The study of the complexation of Sn(ii)-APDDMP and Sn(iv)-PEIMP, considered as potential therapeutic agents for bone metastases by Jansen, David R
  
 
 
 
 
 
 
 
The copyright of this thesis vests in the author. No 
quotation from it or information derived from it is to be 
published without full acknowledgement of the source. 
The thesis is to be used for private study or non-
commercial research purposes only. 
 
Published by the University of Cape Town (UCT) in terms 
of the non-exclusive license granted to UCT by the author. 
 
Un
ive
rsi
ty 
f C
ap
e T
ow
n
The study of the complexation 
of Sn(II)-APDDMP 
and Sn(IV)-PEIMP, 
considered as potential therapeutic 
agents for bone metastases 
s dissertation was submitted to the 
University of Town 
in fulfillment of the requirements for degree of 
MASTER OF SCIENCE 
By 
David R. Jansen 
B.Sc(Hons) University of Cape Town 
• (TNI\TERSITIT necsa ~ 
We're in your world .~ 
C)F C=LL\PE Tl)\\TN NUCLEAR TECHNOLOGY & SERVICES 
Un
ive
rsi
ty 
of 
Ca
pe
 To
wn
The study of the complexation of 
Sn(II)-APDDMP and Sn(IV)-PEIMP, 
considered as potential therapeutic agents 
for bone metastases 
D.R. Jansen 
Department of Radiochemistry, Necsa, PO Box 582, Pretoria, 000 1, South Africa, 
.ct'lvidj({;L!necsa.co.za 
• 
necsa ~ 
We're in your world /~ 
NUCLEAR TECHNOLOGY & SERVICES 
The research described in this thesis was funded by Necsa (South African Nuclear 
Energy Corporation, Ltd.). All experiments were conducted in the department of 
Radiochemistry, Necsa. 
Un
ive
rsi
ty 
of 
Ca
pe
 To
wn
CONTENTS 
TABLE OF CONTENTS 
Acknowledgements v 
Abstract VI 
List of Abbreviations Vill 
1. Introduction and Theory 1 
1.1 Introduction I 
1.2 Potentiometry 5 
1.3 Speciation and Modell ing 9 
1.3.1 ESTA 10 
1.3.2 ECCLES, Blood Plasma Modelling 13 
1.4 Research objectives 15 
1.5 Thesis outline 16 
1.6 References 17 
2. Speciation of APDDMP with SnIl 21 
2.1 Introduction 21 
2.2 Method 22 
? ,., 
_ ..) Results and discussion 
2.3.1 Protonation titrations 23 
2.3.2 Complexation ojAPDDAfP with Sn fl 26 
2.4 Conclusion 32 
2.5 References 34 
3. Speciation of APDDMP with major metal-ion components in 
blood plasma - Call, MglI and Zn" 35 
3.1 Introduction 35 
3.2 Results 36 
3.2.1 Ca-APDDMP model 38 
3.2.2 Mg-APDDMP model 40 
3.2.3 Zn-APDDMP model 42 
11 
Un
ive
rsi
ty 
of 
Ca
pe
 To
wn
4. 
5. 
3.3 
3.4 
3.5 
Discussion 
Conclusion 
References 
Determination of the formation constants for the complexation 
of PEI-MP with Sn lV by glass electrode potentiometry 
4.1 Introduction 
4.2 Method 
4.3 Results and discussion 
4.3.1 Proton dissociation constants 
-1.3.2 IV Sn -(PEI-A1P)formation constants 
4.4 Conclusion 
4.5 References 
Rationalising the high kidney uptake of 117mSn_APDDMP 
in rats by Blood Plasma Modelling using ECCLES 
5.1 Introduction 
5.2 Procedure 
5.3 Results 
5.3.1 First hypothesis 
5.3.2 Second hypothesis 
5.3.3 Third h)pothesis 
5.4 Discussion 
5..1.1 Blood plasma modelling 0/SnI1-APDDMP at 
clinical concentrations 
5.4.2 Rationalisation of hypotheses 
5.5 Conclusion 
5.6 References 
III 
CONTENTS 
43 
46 
47 
48 
48 
49 
50 
50 
52 
59 
60 
61 
61 
62 
63 
63 
70 
77 
83 
83 
87 
91 
94 
Un
ive
rsi
ty 
of 
Ca
pe
 To
wn
6. Conclusion and Future Work 
6.1 Conclusion 
6.2 Future Work 
6.3 References 
IV 
CONTENTS 
95 
95 
99 
103 
Un
ive
rsi
ty 
of 
Ca
pe
 To
wn
ACKNOWLEDGEMENTS 
ACKNOWLEDGE MENTS 
I would like express my gratitude to my supervIsors Dr Jan Rijn Zeevaart and 
professor Graham Jackson for their guidance and contributions toward the completion 
of this thesis. I regard it a privilege to have been mentored by individuals such as 
these, with their wealth of knowledge and experience in the field. Thank you to Jan 
Rijn for his motivation and being an enthusiastic mentor, assisting in my 
understanding of the subject material and for initiating the project. Thank you to 
professor Jackson for his valuable input and advice. 
I would also like to extend a word of thanks to NECSA management - in particular 
Dr Van Zyl de Villiers for support, and for having provided a suitable environment 
for conducting research, and allowing me the liberty of submitting this work toward 
the completion of my MSc degree. 
Thank you to Mrs Deidre Brooks (UCT, Department of Chemistry, administration) 
for her assistance and facilitation of my registration, and for being my 'mediator' 
within the Science Faculty and Department of Chemistry. 
Special thanks to my parents for their support and fervent prayers. I am grateful for 
their selfless sacrifice through the years enabling me to advance toward my intended 
(current) career, and for having inspired me to pursue my ambitions. 
And above ail, I praise God for gIvmg the strength and ability to accomplish 
everything I have up till now. I thank Him for having surrounded me with the right 
people (everyone mentioned above, and the many others that I've failed to mention) 
and providing me with opportunities for personal gro\\1h in all aspects of life. Thank 
God for His perfect design, for His love, mercy and grace. Soli Deo Gloria. 
v 
Un
ive
rsi
ty 
of 
Ca
pe
 To
wn
LIST OF ABBREVIATIONS 
LIST OF ABBREVIATIONS 
APD 
APDDMP 
Bq 
C 
Ci 
Cit or cit 
Cys 
Diphosphonate or bisphosphonate 
DTPA 
l-tIydroxy-3-amino-propylidene-
diphosphonate commercially known as 
Pamidronate™ 
N, N,-dimethylenephosphonate-l-hydroxy-
4-am i nop ropyl idene-d i ph osphonate 
Radioactive decay by emiSSion of an 
energetic beta-particle (electron) 
Bequerel; unit of radioactivity, one decay 
per second 
degrees Celsius 
Curie; unit of radioactivity, 
3.7xIO IOBq 
citrate 
cysteinate 
cUrle 
2-03P-C-PO/- covalent bond. Not easily 
hydrolysed 
Diethylenetriaminepenta-acetate 
electrode constant 
VIII 
Un
ive
rsi
ty 
of 
Ca
pe
 To
wn
ECCLES 
EDTMP 
ESTA 
y 
GEP 
H 
h or hI' 
HEDP 
His or his 
HMDP 
ICP 
J 
LIST OF ABBREVIATJONS 
Evaluation of Constituent Concentration 
Large Equilibrium Systems 
Ethylenediamine-
tetramethylenephosphonate 
Equilibrium simulation for Titration 
Analysis; computer programs suite 
Radioactive decay by emission of an 
electromagnetic y-ray 
Glass Electrode Potentiometry 
proton 
hour 
I-hydroxy-ethylene-diphosphonate also 
known as Etidronate 
histidinate 
Hydroxy methylenediphosphonate 
In 
Inductive Coupled Plasma used for chemical 
analysis 
Joule 
IX 
Un
ive
rsi
ty 
of 
Ca
pe
 To
wn
keV 
L 
LFER 
log [) 
log K 
LWL 
M 
MeV 
MOP 
mY 
n 
Necsa 
pA 
LIST OF ABBREVIATIONS 
kilo electron volt 
ligand 
Liner Free Energy Relationships 
logarithm of the overall formation constant 
logarithm of the stepwise formation constant 
Low-molecular- Weight Ligands 
mol.dm-3 or metal-ion 
mega electron volt 
Methylenediphosphonate also known 
Medronate 
milli volt 
average number of protons per ligand in the 
absence of metal-ion 
South African Nuclear Energy Corporation 
Ltd. 
negative logarithm of the free deprotonated 
ligand concentration 
x 
Un
ive
rsi
ty 
of 
Ca
pe
 To
wn
PEI-MP 
pH 
pKa 
p.m.1. 
Q 
Sal or sal 
153Sm_EDTMP 
117mSn(IV)_DTPA 
99mTc_MDP 
z 
LIST OF' ABBREVIATIONS 
N,N' ,N' -trimethylenephosphonate-
polyethyleneimine 
negative logarithm of the free acid 
concentration 
negative logarithm of the acid dissociation 
constant 
Plasma Mobilisation Index 
32P-orthophosphate, first studies in J 935 
deprotonation function, the average number 
of protons released as a result of 
complexation per metal-ion 
salicylate 
Commercially Quadramee M since 1997. 
Discovered in the 1980s. 
Radiopharmaceutical: Tin(lV)-117m -
Diethylenetriaminepentaacetate 
Commercially known as MDPTM or 
Amerscan TM. 
formation function, the average number of 
protons bound per metal-ion 
Xl 
Un
ive
rsi
ty 
of 
Ca
pe
 To
wn
LIST OF ABBREVIATIONS 
formation protonation function, the average 
number of protons bound per ligand 
XII 
Un
ive
rsi
ty 
of 
Ca
pe
 To
wn
CHAPTER 1 
INTRODUCTION AND THEORY 
1.1 Introduction 
Apart from the common understanding of the skeleton, simply being "the bony or 
more or less cartilaginous framework supporting the soft tissues and protecting the 
internal organs of a typical vertebrate", as described by the Webster dictionary, it is, 
in fact, in itself a rather complex organ with functions more fundamental towards 
sustaining the life of the organism. The skeleton facilitates mobility by providing sites 
of attachment for muscle, it participates in metabolism as the depository for calcium 
and phosphate ions, and very importantly it serves to protect the very sensitive bone 
marrow. During the lifetime of an organism bone tissue undergoes continual 
resorption (destruction) and reconstruction [I, 2] better known as remodelling. The 
two opposing effects work in synch, establishing a reasonable balance within healthy 
individuals. As can be anticipated, this equilibrium is not always static and conditions 
arise to upset the harmony. One such case being osteoporosis, in which the rate of 
resorption exceeds the rate at which new tissue is regenerated, thus resulting in a local 
or systemic bone deficit. Conversely, the excessive and uncontrolled cell division 
within the tissue is also possible, leading to the formation of tumours (irregular 
growths). This disease, better known as cancer, is painful and certainly fatal if not 
diagnosed and treated early. A secondary form of cancer also occurs in which the 
cells from a certain tumour are separated from the organ of origin and transported in 
the body to a different site/organ where it develops [3]. These secondary tumours are 
referred to as metastases. The skeleton is a common site for metastases. Metastatic 
bone cancer usually originates from breast, prostate and lung cancers. 
Interest has mounted in recent years in developing radiopharmaceuticals for 
specifically targeting bone where tissue is over-expressed, as is typical of bone 
tumours. The hope is to identify a drug for effective pain palliative therapy and 
treatment. These studies are geared towards identifying chemical structures that 
exhibit an affinity for bone tissue, as well as and very importantly low levels of 
toxicity to the more sensitive healthy bone marrow. Radiopharmaceuticals make it 
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possible to render an anti-tumour effect at low chemical levels. These therapeutic 
agents are comprised of two key components: a radionuclide (radioactive metal-ion) 
and a ligand with which it is complexed. The individual entities, orland their 
combination, should exhibit an affinity for hydroxyapatite and its components (i.e. the 
main mineral phase of bone) allowing for the selective accumulation in bone, 
particularly concentrating in the affected areas with high bone-turnover. The 
radionuclide is the 'active' ingredient and is responsible for rendering relief upon 
selective uptake at the target site - ideally with negligible damage to healthy tissue. 
Key factors to consider when selecting an effective radionuclide include: (i) the 
ability to produce the radionuclide with high enough specific activity (i.e. high 
amount of radioactivity per mg metal) and radionuclide purity; (ii) radiation 
characteristics; and (iii) the half-life. Ensuring low levels of bone marrow toxicity is 
vital. A radionuclide that could prove promising is radioactive tin-117m ( l17mSn). It is 
particularly novel in that it emits mono-energetic conversion electrons with a discrete 
range (O.2-0.3mm) in bone tissue, which allows for larger bone radiation doses 
without excessive radiation to the bone marrow. Radionuclides that have previously 
been considcred [9] include 153Sm and 166Ho with observed ranges of O.55mm and 
2.7mm, rcspectively. 153Sm and 166Ho emit high energy beta radiation, which do not 
allow for an increase in the administered radiation dose without posing a threat to 
bone marrow in terms of its radiotoxicity. Therefore their therapeutic efficacy is 
compromised due to these dosage limitations. Being an Auger emitting radionuclide, 
117mSn will introducc a highly localized distribution of electrons once inside the cell. 
Furthermore, 117mSn possesses a favourable half-life of 13.6 days. Therefore, by virtue 
of the favourable radiation characteristics that radioactive 117mSn demonstrates, it 
would be beneficial to conduct preliminary experiments with stable isotopes of tin 
(SnlI and Sn1V), in which tin is considered as a component of prospective radio-drugs 
by studying its interaction with potential bone-seeking ligands. Suffice to note that tin, 
in itsclf, is also regarded as bone-seeking [4]. By calculating the relevant equilibrium 
constants (13) - using potentiometric methods and EST A computer analysis, it is 
2 
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possible to predict the speciation of the systems, whereupon the susceptibility of the 
complex to competition within blood plasma can be tested by ECCLES modelling. 
The function of the ligand is to prevent complex dissociation and to facilitate the 
transfer of the radionuclide to the target site. The complex should exhibit a selective 
affinity for the tumour tissue, as in the case of secondary bone metastasis requiring it 
to be bone-seeking. The ligand of choice should selectively accumulate in regions of 
high Call concentration, which is characteristic of areas affected by secondary bone 
metastasis. Phosphonates are known to have a particular affinity for Call. Some 
(di)phosphonic acid derivatives that have been previously considered include EDTMP 
(ethylenediamine-tetramethylenephosphonate) and [l-hydroxyethylidene ]-disphonic 
acid (HEDP) [5]; and also diethylenetriamine penta-acetic acid (DTPA) [6]. Others 
were methylenediphosphonic acid (MOP) [5]; I-hydroxy-3-amino-
propilydenediphosphonic acid (APO) [7]; and more recently N,N-
dimethylenephosphonate-l-hydroxy-4-aminopropylidenediphosphonate (APODMP) 
[8]. Although some of these ligands showed limited success, 153Sm-EOTMP is 
commercially used. The characteristics of 117mSnlV -OTPA appear to be more optimal 
[9] despite the fact that DTPA is not a phosphonate ligand and therefore not a bone-
seeker per se. The effectiveness is derived from 117mSnlV which has a relatively high 
affinity for bone [4]. 
APD had been applied in the inhibition of osteoclast activity by adsorption on the 
bone surface (hydroxyapatite). In addition to minimizing resorption APO served a 
complimentary function in regenerating bone tissue [10] in that, due its mobilisation 
of Call and Mgl! in blood plasma, whereby they are deposited onto bone. Being such a 
versatile ligand, attempts were made to capitalize on its capabilities by complexing it 
to a radioactive metal-ion, and in so doing utilize it as a bone-cancer diagnostic agent; 
e.g. 99mTc_APO for bone scintigraphy [11]. However, in studies with trivalent 
lanthanides such as 166HoIII a neutral complex [MLH]o, and hence, a colloid formed at 
pH 7.4 (where M HOIII, L = APD, H = proton), which resulted in excessive liver 
uptake [7, 12]. Furthermore APO exhibited a high affinity for Cal! which impeded the 
3 
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delivery of the radionuclide 166HoIII to bone. In an endeavour to avert the formation of 
a neutral species, APD was modified by adding two charged methylenephosphonate 
groups at the primary amine centre, resulting in the synthesis of APDDMP - with a 
net charge of 7- (Figure 1.1 a) [13]. APDDMP possesses 8 dissociable protons. 
However, protonation of the tertiaty amine results in an overall charge of 7- in 
solution. 
Figure 1.1a: Molecular structure o/the ligand N,N,-dimethylenephosphonate-
APDDMP 
1-hydroxy-4-aminopropylidene-diphosphonate (AP DDMP) 
A recent approach was to develop/design a water-soluble polymer which is bone-
seeking, and in so doing attempt to exploit the 'Enhanced Permeability and Retention 
Effect' [14] by which these macromolecules passively accumulate in solid tumours. 
This uses the principle that tumours often have ruptured vasculature, which results in 
an increase vascular permeability of the tumour tissue. Therefore particles of the right 
size might escape the vasculature and enter the tumour. The macromolecules are then 
simply retained within the tumour, especially due to an ailing lymphatic system 
within tumour tissue. However, it is important to note that size does matter. By virtue 
of its size, the aim is to avoid uptake by healthy tissue (too small), and accumulation 
within organs such as kidneys and liver (too large). In this study this was achieved by 
functionalizing the water-soluble polymer polyethyleneimine (PEl) with 
methylenephosphonate groups; essentially, the polymerized version of EDTMP, 
called polyethyleneiminomethyl phosphonic acid (PEl -MP) [6, 15] (Figure 1.1 b). The 
optimum fraction of 10 to 30 kDa was determined by Dormehl et al [16]. 
4 
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These two 'newer' ligands were considered in the experiments presented in the 
subsequent chapters 2 to 5, namely APDDMP (N,N-dimethylenephosphonate-l-
hydroxy-4-aminopropylidenediphosphonate) (Chapters 2, 3 and 5) and PEI-MP 
(N,N ',N '-trimethylenephosphonate-polyethyleneimine) (Chapter 4). 
PEI-MP 
Figure 1.Ib: Molecular structure of the ligand N,N',N'-
trimethylenephosphonate-polyethyleneimine (P EI-MP) 
1.2 Potentiometry 
The pnmary technique adopted during the investigation of prospective 
radiopharmaceuticals is that of potentiometry. Fundamentally, the method is based on 
the interpretation of electrode potentials generated by the (electro )chemical 
interaction between Lewis acids (metal ions) and bases (ligands) - demonstrating, 
chemically, the tendencies of a given system placed under certain stresses within 
conditions of interest. 
5 
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The electrode potentials arise due to the movement of electrons between the two 
entities comprising what is referred to as half-reactions. During the reaction the rates 
of the two half-reactions become equal and equilibrium is reached. The individual 
half-reactions do not stop, but continue reversibly. Each half reaction possesses a 
standard electrode potential, P, which is defined as the electrode potential at which 
the activities of all the reactants and products are unity [17]. Electrode potentials are 
measured relative to that of the standard hydrogen electrode (SHE), which being 
reversible, behaves as either an anode or a cathode. This characteristic makes it an 
ideal reference, and can sensibly assume a potential of O.OOOV. Its action as either a 
cathode or anode is determined by the electrode with which it is coupled. By 
convention, the SHE acts as the anode, rendering the electrode potential as a reduction 
potential. The oxidation potential is distinguished by a negative sign. The SHE 
operates by bubbling hydrogen gas (at constant pressure of I atm, and hydrogen ion 
activity of L~ over platinum metal which serves merely as a site for electron 
transfer and does not itself participate in the reaction. The reaction is as follows: 
2H\aq) + 2e' t; H 2(g) 
and schematically represented as 
Pt,H2(p 1.00 atm)I([H+] = 1M)11 
(1.2a) 
(1.2b) 
Essentially, electrode potentials are simply the measure of the extent of reduction; and 
by virtue of its sign, the ease/readiness of the reaction with relative to the standard 
hydrogen potential. 
The electrode potential of a half-reaction can be calculated from the concentrations of 
the individual species comprising the process, as well as the conditions such as 
temperature and, in some instances, pressure. These are substituted into an expression 
known as the Nemst equation, which for a typical reversible half-reaction 
aA + bB + ... + ne- t; cC + dD (1.2c) 
6 
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can be written as 
(1.2d) 
where A, B, C, D represent molecular formulas of the species, e- is the electrons, and 
G, b, C, d are the number of moles of the respective species participating in the given 
half-reaction. EO is the standard electrode potential. 
For example, consider the half-reaction of the SHE above (equation 1.2a). The Nernst 
expression for the electrode potential is given by: 
E=Eo_RTln~ 
nF [H+]2 (1.2e) 
Substituting the constants R = 8.314JK-1mor l , T = 298K (25°C), and F = 96485 C, 
and replacing the natural logarithm with log (base 10), In = 2.303log, the equation can 
be re-written: 
(1.21) 
Note that when a species is a gas the activity/concentration is replaced by the partial 
pressure (atm). Should the reaction have a solid or a pure liquid, the activity assumes 
the value 1, as its concentration is considered to be constant - as too with the solvent. 
The general Nernst equation (l.2d) can thus also be written as 
E = EO _ 0.0592 log [C]'[Dt .. . 
n [Ar[B]h .. . (l.2g) 
Being a very versatile analytical tool, potentiometry provides a means whereby the 
activity of cations and anions in solution can be determined. Its application in this 
regard has been adapted for the purpose of studying the behaviour of potential 
radiopharmaceuticals in an intricate system such as blood plasma. The Nernst 
equation can be derived for calculating the activities of cations or anions. 
For anion A n- E = K + 0.0592 A 
cell P (1.2h) 
n 
and for cation Xn+ E - K - 0.0592 X cell - P (1.2i) 
n 
7 
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(where K = EJ Eref + L, pA -log aA, and pX = -log ax.) 
CHAPTER 
1 
Ecell is the experimentally determined cell potential. The typical cell being represented 
as 
reference electrode I salt bridge I analyte solution I indicator electrode 
Therefore Eccll = Eind - Eref + Ej, where the reference electrode represents a half-
reaction with an accurately known electrode potential and is independent of the 
concentration of the analyte or any other spectator ions in solution. The indicator 
electrode, which, by convention, is treated as the cathode, measures the analyte 
potential, Eind. Across the salt bridge a potential develops at the liquid junctions, the 
net potential of which is given by Ej (net junction potential). 
With potentiometry, small changes in the analyte concentration can be observed, 
which makes it a useful tool for more accurate determination of end-points or 
inflections during titrimetric experiments. The cell potential is measured as a function 
of the titrant volume. Potentiometric titration data provide sequential "snapshots" of 
changes, if any, that a given system (anal}1e) could experience as induced by the 
gradual addition of a reagent. For example, the stepwise dissociation of a ligand 
(Lewis base) such as EDTA (ethylenediaminetetraacetic acid) can be elucidated by 
gradually increasing the pH. The titration data can be analyzed by software programs 
such as ESTA (Equilibrium Simulation for Titration Analysis) [18, 19] during which 
relevant changes, if any, in the system can be interpreted. 
By introducing a metal (Lewis acid) to the ligand analyte, the formation of various 
complexes can be observed as the ligand's protons dissociate with increasing pH. 
These are known as complexiometric or complex-formation titrations. Various 
equilibrium constants can be calculated from cell potentials. Among others, are 
dissociation constants and formation constants (~), which are of greater significance 
for complexation and speciation studies. 
8 
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1.3 Speciation and Modeling 
Radiophannaceuticals are composed of a radioisotopelradionuclide (radioactive metal 
ion) moiety which is bound by/to a ligand to form a complex. Essentially, the ligand 
is responsible for delivering the radionuclide to the target organ where the tumor is 
present. Ideally the ligand should exhibit a relatively high, and selective, affinity for 
the tumour tissue, which serves as a key driving force for directing the drug to the 
target. However, when dealing with intricate physiological/biological systems such as 
the human body, one has to take into consideration the factors that could affect the 
stability of a drug. Upon injection into the body, a drug is exposed to a wide variety of 
other ligands and metal-ions present in blood plasma alone. This could pose a threat 
to the survival of the radio-drug, before it reaches the target site. The ligands present 
in blood plasma could have higher affinity for the metal-ion bound within a given 
complex, or the in vivo metal-ions could easily displace the radioactive metal-ion. A 
successful radiopharmaceutical is one that accumulates selectively at the tumour site, 
having effectively overcome competition, and survived the conditions within blood 
plasma. 
The stability of a complex can be considered in two respects; kinetic and 
thennodynamic. The thermodynamic stability is obtained when the system reaches 
equilibrium and is represented by an equilibrium constant. The kinetic stability refers 
to the rate at which the equilibrium was reached. Thermodynamic equilibria provide 
information about the binding characteristics between metal-ions and ligands, and can 
assist in understanding the behaviour of a complex under certain conditions. Consider 
the general reaction (where M = metal-ion, L = ligand, and N maximum 
coordination number of the metal-ion for the particular ligand (N is dependent on the 
ligand): 
(1.3a) 
The equilibrium can be represented by the overall fonnation constant as follows: 
9 
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(1.3b) 
Alternatively, the thennodynamic equilibrium can be expressed in terms of the step-
wise stability constants: 
(1.3c) 
according to the reaction: 
(1.3d) 
The overall formation constant can also be described as the product of the step-wise 
formation constants. 
I=n 
f3n = K j K 2K 3 .. .Kn = IT K, (1.3e) 
1=1 
For example, a typical reaction (1.3t) 
will produce the following result: 
f3 [MaLhHcl 
{/,n,c - [ML[L]h[HL (1.3g) 
(where M = metal-ion, L ligand, H = hydrogen ions within the complex, and G, b, C 
are the number ofmoJes of the respective participating species). 
The same equation can be used to describe the proton dissociation (protonation) of the 
ligand, when the metal is omitted, i.e. a = O. 
1.3.1 ESTA 
The data obtained from potentiometric experiments can be processed by a computer 
package of programs known as EST A (Equilibrium Simulation for Titration 
Analysis). This robust software package provides an effective means for optimizing 
the data and refining the formation constants, thereby deriving a suitable model that 
best defines the system (interactions of the ligand and metal) of interest. The program 
equates the experimental/real concentrations (~r) with the calculated total 
10 
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concentrations (r,(') in the form of a mass-balance equation, which it attempts to 
solve by Newton-Raphson methods [20]. 
T r =Tc I I (i 1, .. " NC for NC complexes) (1.3.1a) 
Ti is the sum of the individual concentrations of the species comprising the system; 
(1.3.1b) 
where ~ is the species concentration, Xi is the free concentration and k(iJ) is the 
stoichiometric coefficient. 
(J3j = equilibrium constant) (1.3.1c) 
The equations are solved iteratively, by calculating for "NC-free" concentrations, 
whereupon an electrode equation is evaluated so as to obtain the free electrode-ion 
concentrations, [Xk], as observed by the electrode potential 
(1.3.1d) 
(where EZ = electrode response intercept, Ef = electrode selectivity, and E: = liquid-
junction potentiaL). 
The Henderson equation [21, 22] (l.3.1e) is used to correct for changes in the Iiquid-
junction potentials when the glass electrodes are calibrated; 
E J = _ RT In(l +d[X H ]) 
k F I (1.3.1e) 
where I = concentration of background univalent electrolyte. 
The effects of interfering ions are also accounted for by the Eisenman equation [20]; 
(1.3.10 
Effectively, the parameters such as thermodynamic formation constants, [3, and some 
unknown free concentrations can be calculated from other free concentrations and 
parameters - or reasonable estimates thereof that have been experimentally 
11 
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detennined and/or derived from the electrode equations. (The formation constants are 
dependent on the conditions in which they are determined, particularly the ionic 
strength (I) of the medium.) The equations - usually of an absolute-value nature, or 
natural logarithm in the case of [Xk] and 13 - are soluble by simultaneous back-
substitution. The Secant method [23] can also be attempted to solve the equations for 
free concentrations only, in the event that the Newton-Raphson calculation is 
unsuccessful. 
Gauss-Newton algorithms [24] are used to optimize a calculated model representation 
of the experimental data. This is achieved by firstly calculating the experimental 
parameters, such as the initial concentrations of the participating species and 
fonnation constants, at the first and second titration points - from experimental 
values. The free electrode-ion concentration can then be calculated from these initial 
estimates and their respective electrode potentials. Whereupon, the parameters at each 
subsequent point can then be estimated by linear extrapolation from the previous two 
points by considering the change in the electrode potential at each titration point. 
Essentially, the program simulates the experimental titration data in an attempt to 
derive a favourable representation of the fonnation of complexes within the system. 
This iterative process is then repeated until the fitted model - with the estimated 
parameters - is sufficiently refined and close to the solution. The extent, to which the 
calculated parameters fit the experimental data, can be determined by observing the 
standard deviations of the parameters and the Hamilton R-factor [24, 25], and the 
Hamilton R-limit [24, 25] the Hamilton R-factor being a measure of the difference 
between the objective function (parameters being refined) and experimental data 
points. The Hamilton R-limit gives the theoretical minimum of the Hamilton R-factor 
by considering the total number of data points, the number of refined parameters and 
the standard error in the experimental data. Therefore the goodness of fit of the 
calculated model is reflected by the difference between the Hamilton R-factor and the 
R-limit the smaller the difference the better the fit. This sequential analysis of 
titration data allows for the calculation and refinement of parameters such as total 
analytical concentrations, initial vessel and burette concentrations, initial vessel 
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volume, estimation of formation constants, and even the determination of emf values 
and electrode slope. A least-squares method is used to calculate the optimum values 
within groups of identical parameters (same type or value) of a combination of 
titrations, by treating them as a single parameter. The results are interpreted by the 
EST A into the following functions: 
• Z Hand n, the protonation function, which is defined as the number of 
protons bound by the free ligand (in absence of complexation) at respective 
pH values. 
• Z, the complex-formation function, defined as the number of ligands bound 
per metal-jones) at respective pH values. 
• Q, the deprotonation function which describes the number of protons lost by 
the ligand during complexation at respective pH - essentially, the 
displacement of protons by the metal-ion(s) during complex-formation. 
These functions can be translated into graphs by plotting the calculated 
potentials,E~a'c, i.e. pH againstZH or Q(withn), and Z against pA, whereby the 
observed (experimental) functions, E;hS can be compared. 
Once an acceptable model of formation constants has been derived, representing the 
interactions between a ligand and metal-ion of interest, the speciation of the ligand 
can be determined i.e. a distribution of the corresponding complexes/species as they 
form at their relevant pH values. 
1.3.2 ECCLES, Blood Plasma Modeling 
The potentiometric data and EST A analysis thereof provides a reasonably good idea 
of how the system (combination of ligand with metal-ion) will behave in isolation, 
within simulated physiological conditions. However, in order make more accurate 
predictions of the performance of the potential radio-drug, it will be beneficial to 
extend the investigation to compensate for the likelihood (more often than not) of 
competition by physiological ligands and metal ions within the blood plasma. The 
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ECCLES computer program and database can aid in this respect (ECCLES 
Evaluation of Constituent Concentrations in Large Equilibrium Systems [26]). 
1 
In the body, metal-ions can be found as components of proteins, complexed to low-
molecular-weight ligands (L WL) that occur naturally in blood plasma, or as the 
water-solvated aqua-ions. The ECCLES program takes into account the reactions 
between free metal-ions and L WLs. 
The effect of protein binding (irreversibly or reversibly) on metal-ion-LWL equilibria 
is to buffer the free metal-ion concentration such that it remains fairly constant, 
considering that the total concentration of proteins present in blood plasma greatly 
exceeds the total metal-ion concentration, and the free metal-ion concentration is 
significantly less than that of the protein bound metal-ions. Excessive denaturation of 
proteins will be necessary to noticeably influence the free metal-ion concentration 
the equilibrium of which will, most likely, eventually be restored. 
During blood plasma simulations the free metal-ion concentration is fixed, whilst the 
total metal-ion concentration is allowed to vary, but within blood plasma limits. The 
percentage distribution of essential transition metal-ions is calculated as they are 
bound among a host of ligands, forming a vast cocktail of complexes. The 
calculations allow for the complexation of more than one ligand per metal-ion, i.e. 
binary and ternary complexes. The free metal-ions include (in order of decreasing 
concentration in blood plasma): Ca2+, Mg2-, Zn2+, Fe2+, Mn2+, Pb2+, Cu +, Ni2+, Cu2+, 
and Fe3+. 
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1.4 Research objectives 
This study fOnTIS part of the ongoing pursuit for an effective treatment, and pain 
palliative therapy of metastatic bone cancer. The aim is to develop novel 
radiopharmaceuticals which are selective for bone tissue, and capable of providing 
anti-tumour effect with minimal side effects. 
The core components of these radiopharmaceuticals include a radio-active metal-ion 
(radioisotope), which provides the therapeutic effect, and a ligand (Lewis base), 
which serves mainly as a carrier/transporter medium for the radioisotope. This study 
is primarily intended towards identifying these moieties in the context of bone cancer, 
and to elucidate their combined action as potential radio-therapeutic agents. This 
would entail having to design or select suitable ligand structures that exhibit bone-
seeking, as well as tumour accumulation ability. Furthermore, a radioisotope will have 
to be identified that exhibits favourable radiation characteristics with minimal 
radiotoxicity. Once these have been established the complexation behaviour of the 
metal-ion and ligand can be evaluated by potentiometry, and in so doing determine 
the equilibrium constants of formation for the complexes hence their speciation. It 
will also be beneficial to explore the interaction of the selected ligands with major 
metal-ions constituting blood plasma, namely CalI, MgII and ZnlI, providing some 
basic insight into the in vivo action of the respective drug. With the aid of computer 
modelling incorporating the formation constants mentioned above - it is possible to 
account for the likelihood of competition for complexation by free metal-ions and 
ligands typically found in blood plasma. Thereby simulating the binding interactions 
(speciation) of physiological metal-ions and ligands, whereupon predictions can be 
made as to the survival/susceptibility of these drugs within the body, elucidating its 
effectiveness. The blood plasma modelling results could then be used to hopefully 
verify and explain the observed biodistribution of these, and similar 
radiopharmaceuticals as studied in animal experiments reported in literature [27, 28]. 
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1.5 Thesis outline 
Chapter I provides some basic background into the problem that this thesis is 
intended address, namely bone cancer and metastases and the development of an 
effective treatment in the form of radiopharmaceuticals. The fundamental aspects of 
the research methodology is described here, as well as outlining the criteria for the 
design and/or selection of bone-seeking radio-therapeutic agents. The rationale behind 
the selection of both the ligands and the radioisotope considered in this study is 
stipulated. Chapter 2 describes the speciation of SnIl with a phosphonate derived 
ligand, namely N,N-dimethylenephosphonate-I-hydroxy-4-
aminopropylidenediphosphonate (APDDMP) [8]. The subsequent chapter (Chapter 
3) describes the measurement of the formation constants of Call, Mgll and Zn ll with 
APDDMP. The ECCLES database had been expanded to include the complete blood 
plasma model for Snll (for all blood plasma ligands) [13] so as to elucidate the in vivo 
behaviour of Snll-APDDMP, thereby predicting and interpreting biodistribution 
studies during animal experiments (Chapter 5) [27]. Chapter 4 discusses an alternative 
radiopharmaceutical considered for the treatment of metastatic bone cancer, namely 
SnlV -PEI-MP (pEI-MP = N,N' ,N' -trimethylenephosphonate-polyethyleneimine). Snii. 
PEI-MP had previously been reported by Zeevaart et al. [6]. The final chapter 
(Chapter 6) serves to draw to conclusion the broader context of this study by putting 
into perspective the individual components of this thesis; discussing successes, 
constraints and providing recommendations for future work. 
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SPECIATION OF APDDMP WITH SnlI 
2.1 Introduction 
To accurately predict the blood plasma speciation of a potential radiophannaceutical 
the formation constants of such a complex need to be measured. This choice of metal 
ion and ligand were detennined by the following considerations. 
In finding a cure for metastatic bone cancer, one of the key factors to be addressed is 
ensuring that the level of toxicity to the target (bone marrow) is favourably reduced 
if not eliminated. 117mSn with its conversion electrons of discrete energies assists in 
this regard. Exploiting this characteristic allows for an increase in the administered 
dose. Another factor to be considered would be selective accumulation of the drug in 
affected areas - with high bone-turnover. This is characteristic of areas affected with 
secondary bone metastasis. N,N,-dimethylenephosphonate-I-hydroxy-4-
aminopropylidene-diphosphonate (APDDMP) (Figure 2.1) is known to have a high 
affinity for CaIl, and could therefore be suitable to address the problem. 
Glass electrode potentiometry was employed in the study of the complexation of 
APDDMP with Sn ll . Five titrations were carried out, with the following metal to 
ligand ratios; 1: 1, 1:2, 1 :3, 2: 1, 1 Yz: 1. These were conducted under conditions which 
simulated that of blood plasma (in vivo), i.e. [NaCl] := O.ISM. The titration data were 
analysed with the aid of the computer programme EST A, from which it was evident 
that binuclear complexes (M2L - type complexes) were most favoured. Potentiometry 
showed that at the pH of interest for in vivo studies, pH 7.4, the complexes 
[Sn1l2(APDDMP)OHt and [SnlI(APDDMPl] predominate. The effect that 
competing ligands and metal ions, found in blood plasma, have on these species will 
also be shown. 
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APDDMP 
Figure 2.1: Molecular structure o/the ligand N,N,-dimethylenephosphonate-
I-hydroxy-4-aminopropylidene-diphosphonate (AP DDMP) 
2.2 Method 
Complexation with N,N,-dimethylenephosphonate-I-hydroxy-4-
aminopropylidene-diphosphonate (APDDMP) was studied. Five potentiometric 
titrations were conducted with metal to ligand ratios 1: 1, 1 :2, 1:3, 2: 1 and I Yz: 1. 
Conditions were chosen to simulate that of blood plasma, i.e. physiological 
conditions: 25°C, O.15MNaCI. 
In each case the initial pH was set to approximately 1.7 using O.05M HCI solution in 
O.lMNaCI, and was titrated against a O.05MNaOH solution in O.IMNaCI. 
To prevent the oxidation of the Snll to SnlV, all solutions were prepared with de-
aerated water and stored under Argon. The Sn ll salt was also weighed under Argon. 
2.3 Results and discussion 
Data points where precipitation had occurred were excluded from the analysis. 
Analysis of the protonation titrations by EST A rendered the following results for 
APDDMP and its complexes with Snll: 
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Table 2.1. Profonation andformation constants for APDDMP and Snll determined at 
25°C and ]=] 50 mM NaCl. 
Equilibrium! 
.'\np{'lP," # 
logp Number of 
data 
Hamilton 
R-Factor 
log P, 3JDC 
H + HL:;:::::H2L 
H + H2L:;::::: H3L 
H + I-hL:;::::: H4L 
H + H4L:;::::: H5L 
9.79 ± 0.01 
16.83 ± 0.02 
22.74 ± 0.02 
27.68 ± 0.02 
700 0.01736 9.82 
17.03 
23.12 
28.01 
H + H5L ~ H6L 30.04 ± 0.04 30.05 
Snll + OH ~ SnllOH -4.20 * 
SnIl + 2 OH ~ Snll(OH)2 -8.01 * 
Snll + 3 OH Sn ll(OH)3 -17.44 * 
2 Snll + 2 OH ~ SnIl2(OHh -4.16 * 
4 SnIl + 3 OH:;::::: SnIl4(OH)3 -9.55 * 
2SnlI+ LH:;::::: Sn2LH 31.10 ± 0.04 974 0.01406 
2SnIl+ L ~ Sn2L 26.63 ± 0.03 
2SnIl+ L + OH :;::::: Sn2LOH 34.52 ± 0.03 
2SnIl+ L + 2 OH ~ Sn2L(OH)2 40.62 ± 0.03 
2Snll+ L + 3 OH:;::::: Sn:<L(OH)3 44.82 ± 0.03 
2Snll+ L + 4 OH ~ Sn2L(OH)4 48.23 ± 0,05 
SnIl+ L ~ SnL 15.26 ± 0.02 
SnIl+ L + OH:;::::: SnL(OH) 20.30 ± 0.03 
# The charges on the ligands and complexes have been omittedfor simplicity. 
* Hydrolysis constants for SnII were obtained from literature [2 J and included in the 
model. 
2.3.1 Protonation titrations 
Within the pH range of 3 to 10 the experimental data in the Z II curves (Figure 
2.3.1 (aJ) agree favourably with the calculated function. 
The proton dissociation/stability constants of APDDMP are presented in the Table 2 
above. These closely resemble the values reported in literature [1, 3], despite the 
difference in temperature. The graphical representation of the model (Figure 2.3.1 (a)) 
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shows good agreement between the calculated curve and the experimental data. This 
is substantiated by the relatively low R-factor and standard deviations of the stability 
constants. 
5 
4 
3 
1i5 2 
o 
2 3 4 5 6 7 
pH 
8 9 10 11 12 
Figure 2.3.1(a). Experimental (points) and modelled Oines) prolonation 
formation curves for APDDMP. Three titrations are represented by (0) 
1.02mM APDDMP and 6.56mM HCI;(1) 1.49mM APDDMP and 1O.68mM 
HCl and 1.19mM APDDMP and 8.41mM HCI, all titrated against 
50.24mM NaOH in 100.30mM NaC!. All solutions were at 25°C and 150mM 
NaCl or 150mM total ionic strength. 
The proton dissociation constants can be rationalized by comparing them with results 
obtained in literature for similar ligands, such as APD (1-hydroxy-3-amino-
propylidene-diphosphonate) [4] and EDTMP ( ethylenediamine-
tetramethylenephosphonate) [5]. In solution it is expected that the tertiary amine will 
be protonated, and the dissociation constant of this centre has been reported as pKa "" 
11.87 [3]. However, this is not observed (pKa,), therefore it can be assumed that the 
amine remains protonated in solution. This can be confirmed in the presence of a 
metal-ion, whereupon coordinating at the amine site, the proton will be expected to 
dissociate. Amine proton dissociations are typically reported to be higher the pKa 10, 
for example APD exhibits a pKa] 10.95 [4], and EDTMP has two amine centres for 
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dissociation with pKa1 10.67 and pKa2 9.47 [5]. The third and fifth acid 
dissociation constants observed for APDDMP, pKa4 5.91 and pKa2 9.79, are 
consistent with that of two diphosphonate sites for APD, which are 6.01 and 9.80, 
respectively [4]. The pKa3 of 7.04, however, compares best with the protonation 
constant for the methylene-phosphonate centre of EDTMP (7.63) [5]. pKas and pK<l6 
correspond with protonations at the remaining methylene-phosphonate site and a 
diphosphonate site. For the purpose of this study the deprotonated ligand, usually L, 
was defined as H-APDDMP - with the APDDMP remaining protonated at the tertiary 
amine (Figure 2.1). The protonated amine does not dissociate, meaning that the 
completely deprotonated species is not realized. 
The curves tend towards 5 below plf 3, indicating that there are five protonation sites. 
Below pH 10 the graph levels off at 0, suggesting that no further protons are lost. 
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Figure 2.3.1 (b). Species distribution curves for the profanation of APDDMP 
at 25°C and O. J 5M 
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The proposed proton-species distribution of APDDMP can be seen in Figure 2.3.1 (b). 
The inflections viewed in the Z H curve corresponds well with the formation of the 
various species comprising the model. All protons are lost beyond pH 10, and only the 
HAPDDMP species remains. At pH 2 the LH6 species constitutes 40% of the total 
ligand concentration. This supports the high standard deviation observed for LH6. The 
model predicts that a dramatic increase in pH will be needed to exhibit the completely 
deprotonated ligand APDDMP, especially considering the already high basicity of the 
LH species, which is only partially formed (- 45%) at pH 10. At pH 7.4, which is of 
special interest when considering physiological (in vivo) conditions, the predom inant 
species is LH2 (75%) with LH3 being present to lesser degree (25%). 
2.3.2. Complexation of APDDMP with Snll 
2.0 
1 .8 
1.6 
1.4 
IN 1.2 
1.0 
0.8 
0.6 
0.4 
0.2 
2 4 6 8 1 D 12 1 4 1 6 1 8 2D 22 24 26 
pA 
Figure 2.3.2(a}. Experimental (points) and modelled (lines) formation for SnIl 
complexation by APDDMP. pA is the negative log of the free ligand 
concentration. The 5 titrations are represented by (0) 3.41mM Snll and 
I. 66mM APDDMP; (Gl.67mM Snll and 1. 66mM APDDMP; (L1)1.69mM SnIl 
and 3.33mM APDDMP; (V)1.66mM Sn" and 5.00mM APDDMP and 
(+)2.53mM Sn/J and 1.66mM APDDMP. All solutions were at 25°C and 
150mMNaCl. 
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Figure 2.3.2(b). Experimental (points) and modelled (lines) formation for Snll 
complexation by AP DDMP. pA is the negative log of the free ligand 
-
concentration. The dotted line represents the n curve, which is the 
protonation state of APDDMP in the absence of metal. The 5 lilrations are 
represented by (0) 3.41mM Snll and 1. 66mM APDDMP; 1.67mM Snll and 
1. 66mM APDDMP; (L1)1.69mM Snll and 3.33mM APDDMP; (V)1.66mM Snll 
and 5.00mM APDDAfP and (+)2.53mM SnlI and 1.66mM APDDMP. All 
solutions were at 25°C and 150mM NaCI. 
Back-fanning in Z curves (Figure 2.3.2 (a)) at high pH reveals evidence of 
hydrolysis. The curves tend towards 0.5 at low free ligand concentration (low pH), 
indicating the presence of binuclear complexes (e.g. M2L). 
Good agreement can be found between the calculated (modelled) Z curve (Figure 
2.3.2(a)) and the experimental data points, as is true for the Q curve (Figure 1.2(b)) 
as well. 
The Q curves remain relatively constant at 1.5 below pH of 9, after which they rise to 
-
about 4. At pH beyond 7.5 the Q curves cross the n curve, confirming the presence 
of (OH) containing species. The tendency of the Q curves toward 4, at high pH, can 
be interpreted as the species M(OH)4 being present. The behaviour of the curves about 
1.5 implies that three protons are released on complexation per two metal ions i.e. 
2M - 3H+ - verifying the presence of binuclear species (M2L type complexes). 
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Figure 2.3.2(c). Speciation distribution for the complexation of Snlf with 
APDDMP. 
The experimental curves deviated from the calculated curves at pH 10-1]. 
In an attempt to improve on the model, the titrations were separated into two groups; 
one containing those titrations with high ligand content, and the other with the high 
Snl[ content - ]: 1 formed part of the latter. Each set of titrations was modelled 
separately and then recombined to obtain a new model, which was a reasonable 
representation of the two. This, however, proved unsuccessfuL 
The speciation for the Snll complexes with APDDMP can be seen in the Figure 
2.3.2(c). This clearly shows the relative distribution of the SnIl-APDDMP complexes 
as they are formed in tandem. A definite presence of hydroxide complexes is evident 
from pH 5 and beyond, as was expected upon studying the Z and Q curves. At the 
pH7.4 (physiological pH) five complexes are formed: [SnIl.APDDMPt, [SnIl2-
APDDMP(OH)]4-, [SnIl2-APDDMP(OH)2t, [Sn lI-APDDMP(OH)]6-, and [SnII2-
APDDMP]3-, Their respective percentage mole fractions being: 48%, 32%,16%, 3% 
and 1%. 
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For the species SnLOH and Sn2LOH the loss of a proton could be due to hydrolysis of 
water or by dissociation from the ligand (which would be better defined as SnLH_1). 
This is distinguishable by the step-wise formation constant log K1I -] = 5.04 (SnL + 
OH !:; SnLOH), which is greater than that for the hydrolysis of Snll, log K lO-1 -4.20. 
This suggests that, upon coordinating with the metal, the ligand loses a proton rather 
than that of a Sn-bound water molecule. The most likely site for deprotonation would 
be the tertiary amine, thereby freeing the nitrogen lone-pair to bind with Snll(Figure 
2.3.2(d)). This serves to further support the protonation model as evidence of the 
existence of the protonated amine site. Similarly for log K21 -2 = 6.10 (Sn2L + OH !:; 
Sn2L(OH)2), which is much greater than the hydrolysis constant of the binuclear SnIl. 
ion (log K20-2 = -4.16). 
Interesting to consider are the various possibilities for coordination of the Snll.ion(s). 
The possible structures can be deduced - APDDMP being a rather flexible 
polydentate ligand, Sn-APDDMP complexes could take on various forms. The ligand 
could chelate the tin-ion(s) forming rather stable cyclic structures, as illustrated in 
Figure 2.3.2(d) and Figure 2.3.2(e). With the aid ofNMR spectroscopy - i.e. NMR 
titrations, which was outside of the scope of this study - more accurate predictions 
can be made. 
-0 0 
\ // 
/p,) 
Q / O~ /0-
~-'N~P-Q 0) .... OHlSrV 
"P ,'e.!Y 
/ \\ _:::::P-O 
-0 0 0 '0-
Figure 2.3.2(d}. Proposed structure for binuclear SnfJrAPDDMP(OH) 
complex. Showing two sites for coordination of SnfI: (i) an amine and 
methylene-phospho nate site (bicyc/o[3,3, OJ), and (ii) a diphosphonate 
site (6-membered ring). 
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The coordination of the SnIl-ion at the amine centre could lead to the formation oftwo 
stable 5-membered rings (a biclyclo[3,3,0]-species) - with additional interactions of 
the methylenephosphonate groups (Figure 2.3.2(d)). This type of chelation is possible 
for both the binuclear and mononuclear species (Sn2LOH and SnLOH). By taking into 
consideration one further interaction at the diphosphonate binding site, to include 
coordination at the alcohol, this could afford the formation of another bicyc1ic system 
(bicylco[2,2,1 ]-species) as illustrated in Figure 2.3.2(e). 
0\ 0 
'\ I p-o 
Figure 2.3.2(e}. Proposed structure for binuclear Sn1l2-APDDMP(Oll) 
complex. Showing two sites for coordination of Snll : (i) an amine and 
methylene-phosphonate site (bicyclo[3,3,Oj), and (ii) a diphosphonate 
site including coordination at the alcohol (bicyclo[2,2, 1 j). 
In order to distinguish between the methylenephosphonate and diphosphonate 
interactions to distinguish the formation constants of Snll-APDDMP can be compared 
with that of another ligand comprising only the diphosphonate functionality, namely 
HEDP (l-hydroxyethylene-diphosphonate) [6]. The complexation of HEDP with Snll, 
to form Snil-HEPD, results in the formation constant of 10g(3l1o = 14.76 [6]. This 
closely resembles the same species obtained for APDDMP, i.e. )og(3l1o 15.26. 
Therefore it is safe to assume that the Snll-ion would initially coordinate at the 
diphoshonate site forming Snll-APDDMP (Figure 2.3.2(/)), and would migrate to the 
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methylenephosphonate region upon deprotonation of the amine, to form Snll~ 
APDDMP(OH) as explained above and illustrated in Figure 2.3.2(j). 
0\ ° '\ / p-O 
O~O 
\ I 
0' 
1 
H 
/~ 
+OH 
--
log K= 5.04 
Snll-APDDMP(OH) 
Figure 2.3.2(j). Proposed structure for Snlf~APDDMP species. 
Showing the initial coordination of Snll at the diphosphonate site, and 
the subsequent coordination at the methylenephosphonate site 
folloWing the deprotonation of the tertiary amine. 
The same comparison cannot be made for the binuclear species SnII2L ofHEDP, since 
the value reported by Claessens et al [7] log13210 = 25.3 was measured using 
(CH3)4NN03 as background electrolyte with 1 0.1 M. However, this does reveal that 
it is possible for two metal-ions to bind at the diphosphonate site to form SnII2-
APDDMP. It can be postulated that upon deprotonation of the amine that at least one 
of the metal~ions could migrate towards the methylenephosphonate site to form Snllr 
APDDMP(OH). Furthermore, the formation constant for that of Snll with PEI-MP 
(N,N' ,N' -trimethylenephosphonate-polyethyleneimine) [6] can be considered, which 
consists purely of methylenephosphonate groups. The value of the equilibrium 
constant obtained for the formation of SnIl2-APDDMP exactly matches that of SnII2-
PEI-MP as reported by Zeevaart et al [6]. This clearly indicates the preference for the 
Snll-coordination at the methylenephosphonate site for the SnIl2-L complex of 
APDDMP. Therefore, both the diphosphonate and the methylenephosphonate sites 
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will most likely be occupied by Snll-ions initially (for SnIlrAPDDMP) with the amine 
remaining protonated. Deprotonation of the amine would then result in the additional 
coordination of the nitrogen lone-pair to form the type of species depicted in Figure 
2.3.2(e), SnllrAPDDMP(OH). The step-wise hydrolysis of the SnIIrAPDDMP 
complexes, and their formation equilibria, coincide with that of the SnIJ2-PEI-MP [6], 
with the exception of the M2L(OH)4 species, which is unique to APDDMP (Table 
2.2). Also common to both APDDMP and PEI-MP is the formation (and magnitude of 
the equilibrium constant) of the M2LH species. 
Table 2.2. Comparison of the step-wise formation constants for complexation 
ofSnIl with APDDMP and PEI-MP[6], as determined at 25°C and 1=150 mM 
NaC!. 
Equilibrium! APDDMP PEI-MP 
Species log K log K 
~~.~~~~ ... _~ ... ~_ ... _~_ ~ls w01J!1~_ ~~L __ 
2Sn"2L + H !:; Sn2LH 
2SnlI+ L !:; Sn2L 
Snll2L + OH !:; Sn2LOH 
SnIl2LOH + OH !:; Sn2L(OHh 
Sn1I2L(OH)2 + OH Sn2L(OHh 
SnII2L(OH)) + OH .!:; Sn2L(OH)4 
Snll+ L .!:; SnL 
SnIlL + OH !:; 
2.4 Conclusion 
4.47 :to.04 
26.63 :to.03 
7.89 :to.03 
6.10 :to.03 
4.20 :to.03 
3.41:t 0.05 
15.26:t 0.02 
5.04:t 0.03 
4.15 ± 0.04 
26.62 ± 0.04 
8.46 ± 0.03 
6.05 ± 0.03 
3.75 ± 0.03 
In the protonation and the Snll complexation curves for APDDMP (i.e. Z H , Z and 
Q curves), the calculated function follows the experimental data very closely (Figures 
2.3.l(a), 2.3.2(a), 2.3.2(b)). It can be deduced that no further protons are lost before 
pH 12 as the curves level off at zero towards the higher pH region. At low free-ligand 
concentrations, the Z curves (Figure 2.3.2(a)) shows an inflexion at 0.5, suggesting 
the existence of binuclear (M2L) complexes. Furthermore, the Z curves exhibit back-
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fanning, which is indicative of hydroxy-species being formed. The Q curves (Figure 
2.3.2(b) remain constant at 1.5 from pH 2 to 9, implying that 3 protons are lost for 
every 2 metal ions; confirming the presence of binuclear species. Beyond pH 7.5 the 
Q curve rises above the n curve, confirming the existence of hydroxy-species 
(MLOH - species). 
It is clear that APPDMP favours the formation of binuclear complexes with Snll. At 
the pH of interest for potential in vivo studies (pH 7.4) three complexes are observed: 
[Snll-APDDMP( (47%), [SnII2-APDDMP(OH)t-(32%), and [SnIl2-
APDDMP(OHhtC18%). In the model presented above, there is a discrepancy as to 
whether the SnL(OH) species should be included. Excluding the SnL(OH) complex 
results in only a slight increase in the Hamilton R-Factor (0.0 IS). Its presence also 
only slightly improves the Q curves at pH 10-11. Hydrolysis of SnIl occurs at high 
pH, as can be evident in the species distribution diagram - Figure 2.3.2(c}. The 
presence of the Sn(OII) results in the 'distortion' of the data in the high pH region, 
accounting for the deviations observed in the Q curves at pH 10-11. 
We've also managed to show similarity in the binding characteristics of APDDMP 
and PEI-MP [6] when forming M2L -type (binuclear) complexes. 
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CHAPTER 3 
SPECIATION OF APDDMP WITH MA.JOR METAL-ION COMPONENTS IN 
BLOOD PLASMA - Call, MglI AND Zn ll 
3.1 Introduction 
To effectively understand the behaviour of the ligand within the blood plasma, the factors 
affecting its action have to be taken into consideration. Rationalising the affinity of the 
ligand for the target material, and the stability of a given metal-ligand complex when 
introduced into a complex system such as the blood plasma are key aspects of the 
development of a potential radiopharmaceutical. 
The ligand, whose function is to carry the radionuclide to the target site, should exhibit an 
affinity for the tumour tissue, essentially making it bone-seeking. The ligand of choice 
should selectively accumulate in regions of high Call concentration, which is 
characteristic of areas affected by secondary bone metastasis. Phosphonates are known to 
have a pm1icular affinity for Call. Some (di)phosphonic acid derivatives that had been 
previously considered include ethylenediamine-tetramethylenephosphonate (EDTMP) 
and [l-hydroxyethylidene ]-disphonic acid (HEDP) [1]. Less successful were phosphonate 
ligands methylenediphosphonic acid (MDP) [I]; and I-hydroxy-3-amino-
propilydenediphosphonic acid (APD) [2]. Studies had also been performed on EDTA-
type (ethylenediaminetetra-acetic acid) derivatives, such as d iethyl enetriamine-penta-
acetic acid (DTPA) [3], and proved not to be as effective a bone-seeking agent [4,5]. 
The first step to elucidating the complete behaviour of a radiopharmaceutical would be to 
conduct speciation experiments. These experiments aid in understanding the function of 
the ligand or metal-ion in blood plasma. Blood plasma modelling is of interest as it serves 
as an effective tool for predicting the in vivo behaviour of the complex. before pursuing 
clinical trials. One such success story was 153Sm_EDTMP; the blood plasma model 
closely matched the clinical observations [7]. Establishing a similar model for APDDMP 
would entail having to measure the formation constants of the ligand with the major 
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metal ion constituents found in blood plasma, such as Call, MglI, and Znll. To a large 
extent, these constants can be obtained from literature, and at different ionic strengths and 
temperatures. 
The technique employed is that of glass electrode potentiometry. Titrations were 
conducted in a manner so as to closely simulate physiological conditions, i.e. an ionic 
strength (I) of O.15mol.dm-3 T\aCI all solutions were prepared isotonic to blood plasma. 
ln so doing the ionic strength could effectively be maintained throughout the 
experiments. Titration data were refined with the aid of a software programme EST A, 
from whence the formation constants were calculated. However, a temperature of 25°C 
was deemed appropriate, as opposed to 3rC (physiological conditions) - since the results 
for the protonation of APDDMP as observed at both temperatures were in good 
agreement (see paragraph 3.2 below). 
3.2 Results 
The following models were obtained in the study of the complexation of APDDMP with 
Call, Mgll and Znll. Attempts to reproduce the exact models previously reported were 
unsuccessfu I. 
The results (Table 3) differ from those reported by Zeevaart el at. [3] as the titration 
conditions differ. For the purpose of these experiments it was considered suitable to 
conduct experiments at 25°C so as to be consistent with the majority of formation 
constants reported in literature and in the ECCLES database. FUl1hermore, the lower 
temperature of 25°C was easier to maintain, minimizing evaporation and condensation 
within the vessel, which could affect the reproducability afthe results. There was very 
little or no difference in results obtained for the protanation constants of the ligand, for 
experiments conducted at 25°C as compared to literature data (37°C), hence justifying the 
use of the lower temperature. 
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Table 3. Profonation andformation constants for complexes of APDD1'vfP with Call, MgH 
and Zn7/, determined at 25°C and J= J 50 mlvf NaC!. 
Equilibrium! logfi Number of Hamilton log p, 3JOC 
_~pecies # ....... _.~_ ...... _~._ ..... [This workJ data points R-Factor Zeevaa.r!f1L 
.... . ... - ..... 
H +HL~thL 9.79 ± 0.01 700 0.01736 9.82 
H + H2L~ H3L 16.83 ± 0.02 17.03 
H + H3L -' H4L 22.74 ± 0.02 23.12 
H+H4L~ H5L 27.68 ± 0.02 28.01 
H + H5L~ H6L 30.04 ± 0.04 30.05 
LH3 ~ Ca2LH3 30.89 ± 0.03 600 0.00637 
2CaII+ LH2 ~ Ca2LH2 25.74 ± 0.03 24.20 
2Ca([+ LH ~ Ca2LH 20.54 ± 0.03 18.29 
2CalI+ L ~ Ca2L 14.34 ± 0.03 10.99 
2CaII+ L + OH..,- Ca2LOH 20.29 ± 0.03 
Ca!I+ L + H ~ CaLH Not observed 13.87 
Call+ L + OH ~ CaLOH Not observed 8.60 
Call + L + 20H ~ 14.68 ± 0.02 11.61 
LH3 ~ Mg2LH3 30.46 ± 0.03 750 0.00918 
2Mgll+ LH2 ~ Mg2LH2 25.41± 0.04 24.16 
2Mgll+ LH ~ Mg2LH 20.26 ± 0.03 18.44 
2MglI+ L ~ Mg2L 13.48 ± 0.04 11.10 
2MglI+ L + OH ~ Mg2LOH 19.93 ± 0.04 4.47 
2Mg"+L+20H Mg2L(OHh 24.51± 0.04 
L+20H~ Not observed 12.19 
LH3 Zn2LH3 31.19 ± 0.03 727 0.00496 
2Znll+ LH ~ Zn2LH 23.36 ± 0.02 
2Zn"+ L ~ Zn2L 18.23 ± 0.03 
2Znll+ L + OH ~ Zn2LOH 26.31 ± 0.03 
2Znll+ L +20H ~ Zn2L(OHh 32.53 ± 0.03 
ZnIl + L + OH ~ ZnLOH 16.36± 0.02 13.46 
ZnII+ L + 20H..,- ZnL(OH)2 Not observed 15.49 
Znll+ L ~ ZnL Not observed 9.53 
Znll+ L + H ~ ZnLH Not observed 16.72 
Znll+ L + 2H ~ ZnLH2 Not observed 22.75 
Znll+ L + 3H ZnLH3 Not observed 27.01 
# .. . m 
The charges on the hgands and complexes have been omitted for simplicity. 
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3.2.1 Ca-Apddmp model 
2.2 
2.0 
1.8 
U 
1.4 
1.2 
IN 1.0 
o.a 
II.G 
OA 
Q.2 
0.0 
.Q.2 
2 • " 8 lD 12 14 16 18 2D 22 24 
pA 
Figure 3.2. 1 (a). Experimental (points) and modelled (lines)formationfor Calf 
complexation by APDDMP. pA is the negative log of the free ligand 
concentration. The 3 (itrations are represented by (O) 1.3BI11M Ca" and 1.61 mM 
APDDMP; (,1) O. 70mMCa ll and 1.63mM APDDlvfP; 1.-IBnl1VfCaf / and 
-I.-I7mAI APDDMP. All solutions were at 25°C and 150m,o/fNaCl. 
4 
10 2' 
. I 
, ;, 
o 
~~~--~~~~~~~~--~~~~~~ 
1 2' $ 4 5 e 7 8 9 10 11 12 
pH 
Figure 3.2. 1 (b). Experimental (points) and modelled (lines) formationf(Jr Call 
complexation by APDDMP. The dotted line represP;11s the n curve, which is the 
protonation state of APDDMP in the absence of metal. The 3 titrations are 
represented b)-I (0) 1. 3 Bm1vl Call and 1.61mM APDDMP; (,1) O. 70mlvfCa// and 
1. 63mM APDDA1P; (~) l.4BmM Ca" and .:t.-I7mM APDDMP. All solutions were 
at 25°C and 150mAf NaCl. 
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Figure 3.2. 1 (c). Species distribution 
APDDMP. 
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3.2.2 Mg-Apddmp model 
2.2 
2.0 
i 
1.8 . 
1.8 
1.4 
1.2 
IN 1.0 \£ 0.8 
0.6 
004 
0.2 
0.0 
·0.2 
2 4 6 8 '0 12 14 18 18 20 22 24 
pA 
Figure 3.2.2(a}. Experimental (point5) and modelled (line5) formation/or lV/gil 
complexation by APDDMP. pA is the negati've log of thefree ligand 
concentration. The 3 titration.') are represented by (0) 1.54mM lVlgff and 1.61mM 
APDDMP; (1) O. 78mlv! Ml' and 1.65mM APDDMP; (:....] 1.55mM Afg" and 
-I. 87mlvl APDDAlP. All solutions were at 25°C and 150mM NaC!. 
5~----------------------------------, 
4 
I 
o 
·tL ..... ~.~.~~~"_~ __ .~~~ . l.~~.~~L ....•. ~ .. ~~~ ...... L~._~ 
1 2 3 4 5 (I 7 8 II 10 11 12 
pH 
Figure 3.2.2(b). Experimental (points) and modelled (lines) formation/or Mgll 
~ 
cornpiexation by APDDMP. The dotted line represents the n curve, which is the 
protonation state of APDDMP in the absence of metal. The 3 titrations are 
represented by (0) 1. 54mM All' and i.6lrnM APDDA1P; (.d) O. 78mM Mglf and 
1.65mM APDDMP; (~) 1. 55mM Mgl! and 4.87mMAPDDMP. All solutions 'were 
at 25°C and 150mM NaC!. 
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Figure 3.2.2(c). Species distribution jar the complexation of MgII with 
APDDMP. 
41 
Un
ive
rsi
ty 
of 
Ca
pe
 To
wn
SPECIATION OF APDDMP WITH Cal!, Mgll AND ZnlI CHAPTER 3 
3.2.3 Zn-Apddmp model 
2A 
1.9 
..0.1 
2 4 e 8 10 12 14 1G 18 20 22 24 
pA 
Figure 3.2.3(a). Experimental (points) and modelled (lines) formationfiw Sn lf 
complexation by APDDlvlP. pA is the negative log of the free ligand 
concentration. The 3 titrationr.; are represented by (0) 1. 51 mAl z,i' and 1. 61 mM 
APDDA!P; (,1) O. 76mM Zn ff and 1. 66mlVi APDDMP; 1. 57mM Znl! and 
-I. 65mM APDDMP. All solutions were at 2YC and 150mM NaC!. 
er-----------------------------------~ 
... 
3 
/0 2 
o· 
~~~~~~--~--~~--~--~~--~~~ 
1 2 3 4 S 8 7 8 9 10 11 12 
pH 
Figure 3.2.3(b). Experimental (points) and modelled (lines) formation for Snl! 
complexation b.v AP DDMP. The dotted line represents the n curve, which is the 
pr%nation state ofAPDDMP in the absence of metal. The 3 titrations are 
represented by (0) 1.51mM Znfl and 1.61mAIAPDDiV[P; (Ll) O. 76mlv[ Zn f ! and 
1.66mM APDDMP; (~) 1. 57mM Zn" and -I. 65mA! A PDDMP. All solutions were 
at 25°C and 150mM NaC!. 
42 
Un
ive
rsi
ty 
of 
Ca
pe
 To
wn
SPECIATION OF APDDMP WITH Call, MgII AND Zn" CHAPTER 3 
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Figure 3.2.3(c). Species distribution for the complexation of ZnIl with 
APDDMP. 
3.3 Discussion 
The Mg-Apddmp model was the most troublesome, and as a result a good fit could not be 
obtained with the experimental and calculated data as is evident in the Q and Z curves. 
Ilowever, the model presented above proved to be the most sensible. 
As observed in the Z curves for all three systems APDDMP with Call, Mgll and Znll-
the calculated models (lines) follow the experimental data points. At high free ligand 
concentration the curves exhibit back-fanning, indicating that the APDDMP form 
hydrolysed complexes with the metal ions. 
The modelled Q curves (lines) show a relatively good fit with the experimental data 
(points). For the Call and MglI systems the Q curves average at 0.5 between pHs 3 and 7. 
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Hence the formation of binuclear complexes can be expected (i.e. two metal centres per 
-
one ligand unit, M2L). Beyond pH 8 the graphs gradually rise above the n curve, 
indicating that more protons are dissociated than are available from the ligand. This 
supports earlier observations of the Z curves, from which the formation of hydroxy-
complexes was anticipated. The Zn"-APDDMP system differs from the rest slightly in 
that the Q curves flatten at 0.5 below pH 3 only, whereupon it rises to 1.5 where it stays 
relatively constant. In both cases the species that form may still be binuclear (of the type 
tvhL), but they differ in the number of protons that dissociate per metal ion that the ligand 
complexes with. For example, should a single proton dissociate for every two metal ions 
that complexes with APDDMP, the result will be a Q of 0.5. The Q curves remaining 
constant at 1.5 could be the result of three protons dissociating per every two metal ions 
that form a complex with APDDMP. At approximately pH 7.5 the Q curves rise above 
the ~ curve to substantiate the existence of hydrolysed Zn ll complexes. 
The following complexes were most prominent at pH 7.4 (physiological conditions), as 
extrapolated from the speciation curves (where L H-APDDMP with a net charge of7-): 
• Ca-APDDMP [Ca1l2Lf 69.0% 
[CaIl2L(OH)]4. 27.5% 
[CaIl2LHf' 3.5% 
• iVJg-APDDlyfP [MgIl2L(OH)] 4- 52.0% 
[Mg1l2L( 39.0% 
[Mg"2LHt 7.5% 
[Mgii2L(OHh ]5. 1.5% 
• Zn-APDDlvIP [ZnI12L(OH)]4. 54.0% 
[Zn llzL(OHh]5' 40.0% 
[Zn IlL(OH)]6. 5.0% 
[Zn"2L]3. 1.0% 
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The ligand protonation constants can be interpreted in terms of the chemical environment 
in which they occur. An effective technique for investigating the proton dissociations 
would be by NMR-spectroscopic titrations. However, in the absence of this technique it is 
possible, by making use of the wealth of formation constants that are available in 
literature, to compare for the individual components constituting the ligand, which in the 
case of APDDMP are diphosphonates, methylene-phosphonates and a tertiary amine. 
Two phosphonate derived ligands that exhibit identical functionalities to that of 
APDDMP are APD (l-hydroxy-3-amino-propylidene-diphophosphonate) [2J and 
EDTMP (ethylenediamine-tetramethylenephosphonate) [6]. When in solution the ligand 
will instantly assume a proton at the tertiary amine centre. With a dissociation constant as 
high as pKa 11.87 [8], the species is fairly stable and hence the ligand remains 
protonated in this region. When evaluating the proton dissociation of the ligand it is 
evident that the amine proton does not appear within the model, and therefore it is 
necessary to redefine the ligand APDDMP as LH. By comparison to APD (pKaJ 10.95) 
[2] and EDTMP (pKa, 10.67 and pKa2 := 9.47) [6], the dissociation of the amine proton 
usually exceeds pKa = 10. This existence of APDDMP in the protonated form can be 
further substantiated when coordinating with a metal-ion, whereupon the dissociation of 
the amine proton would be realised, and can then be evaluated in terms of the first 
hydrolysis equilibrium constant of the complex against that of the metal-ion. Observed 
acid dissociation constants of APDDMP, pKa2 9.79 and pKa4 =5.91, correspond well 
with that of two diphosphonate sites of APD, i.e. 9.80 and 6.01. The dissociation 
represented by pKa3 7.04 agrees best with the methylene-phosphonate site of EDTMP, 
which is 7.63. The remaining protonation sites methylene-phosphonate and 
diphosphonate - are represented pKas and pKa6. 
The complexiometric models for Call, MglI and Zn" with APDDMP could not reproduce 
literature speciation models [3]. Furthermore, the results obtained could also not be 
matched with similar systems of ligands comprised of the individual components of 
APDDMP, i.e. diphosphonate and methylenephosphonate functional groups. Ligands 
such as [l-hydroxyethylidene]-disphonic acid (HEDP) (l], methylenediphosphonic acid 
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(MOP) [I], l-hydroxy-3-amino-propilydenediphosphonic acid (APO) [2], and N,N',N'-
trimethylenephosphonate-polyethyleneimine (PEI-MP) [9]. 
3.4 Conclusion 
The protonation speciation model for APOOMP compared very well with the literature 
data considering the difference in temperature, although the complexation models were 
not reproducible at 25°C. 
The proposed models calculated for the three systems studied here ~ namely APDOMP 
with Call, MglI and ZnIl_ were in good agreement with the experimental/observed data. 
Binuclear complexes CvhL ~ type species) are formed with each of the three metals. The 
complexes that were most dominant within the region of interest (physiological pH 7.4) 
were M2L for Call and M2UL j for Mgll and Znll. 
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CHAPTER 4 
DETERMINATION OF THE FORMATION CONSTANTS FOR THE COMPLEXATION 
OF PEI-MP WITH SnlV BY GLASS ELECTRODE POTENTIOMETRY 
4.1 Introduction 
In the pursuit for a cure for metastatic bone cancer the complexation of N,l\' ,N'-
trimethylenephosphonate-polyethyleneimine (PEI-MP) Figure 4.1 - with SnlV was 
considered. PEI-MP is known for its high affinity for Call, and is therefore an ideal ligand 
for selective accumulation in affected bone. 
A successful radiopharmaceutical is one that selectively accumulates at the target tumor 
'vvithout posing any threat to healthy, non-cancerous tissue. In developing palliative and 
therapeutic agents for metastatic bone cancer, two criteria have to be met. Firstly, the 
ligand should be selective for calcium and accumulate especially in regions of high Call 
concentration as is typical of bone tumors. Secondly, the metal of choice should render 
minimal toxicity to the sensitive bone marrow. 
The metal-ligand system considered here is that of Sn lV and a methylenephosphonate-
functionalised polyethyleneimine, namely PEI-MP. 117mSn iV is proposed, as it emits low 
energy electrons, which will comply favourably with minimizing the toxicity to the bone 
marrow. Furthermore, lower levels of toxicity would make it possible to administer larger 
doses, thereby ensuring the effectiveness ofthe pharmaceutical. The high calcium affinity 
of PEI-MP will aid in delivering and accumulating the r::dioactive 117mSn at the target 
site. 
To gain some understanding into the behaviour of 117mSnIV_PEI_MP complexes in blood 
plasma, the formation constants were measured using glass electrode potentiometry. 
Titrations were carried out with an ionic strength of O.ISM NaCl to simulate blood 
plasma, and at 25°C. The challenge was to avoid the hydrolysis of the SnIV, and hence 
precipitation. Several attempts at different titration techniques were fruitless. One such 
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experiment involved titrating the PEI-MP with an acidified solution of SnIV, while 
maintaining a constant pH - using O.OSM NaOH. In so doing observe the changes in 
complexation as the concentration of Sn is increased relative to the PEI-MP. A series of 
titrations were conducted at various pHs, and the data were analyzed using the EST A 
modeling program. The data would not refine, and hence the model was insoluble. 
However, the method presented here is that of typical complexiometric titrations whereby 
the ligand-metal interactions were monitored by potentiometry, whilst varying the pH -
titrating with an isotonic solution of O.OSM NaOfI. 
PEI-MP 
Figure 4.1: Molecular structure of the ligand N,N',N'-trimethylenephosphonate-
polyethyleneimine (PEI-MP) 
4.2 Method 
The formation constants for the complexes that PEI-MP forms with SnlV were 
obtained by glass electrode potentiometry. Three titrations were conducted, of which 
the data were analysed using ESTA. The metal-to-ligand ratios for the titrations were: 
1:2, 2: 1 and I 'li: 1; these were performed with I = O.ISM NaCI (simulating blood 
plasma conditions). The challenge, however, was the unavoidable hydrolysis of SnIY, 
which resulted in the formation of precipitate during the course of the experiment. 
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The data points corresponding to the formation of precipitate (visible) were omitted 
from the EST A modelling. 
4.3 Results and discussion 
Table 1. Protonation andformation constants for PEI-MP and Snll'-PEI-MP as 
determined at 25°C (I = O.15M NaCl). 
Equilibrium! logp Number of Hamilton 
S . # data points R-Factor peeles 
H+ L;=HL 9.683 ± 0.007 750 0.01207 
H + HL..- H2L 17.461 ± 0.009 
H + H2L;= H3L 23.788 ± 0.010 
H + H3L;= H4L 27.780 ± 0.012 
SnlV + OH;= SnOH -1.94 * 
SnlV + 6 OH ;= Sn(OH)6 -24.11 * 
2Sn1v +L-3H;=SnIV2L(OH)3 39.971 ±0.100 357 0.01729 
2SnIV +L- 4H;= Snlv2L(OH)4 36.658 ± 0.021 
2SnIV 5H;= Snlv2L(OH)s 27.402 ± 0.032 
2Sn1v 6H;= Snlv2L(OH)6 18.637 ± 0.059 
2Sn1v +L-7H;= SnIV2L(OHh 9.634 ± 0.053 
# The charges on the ligands and complexes have been omitted for simplicity. 
Logp 
IlL 
9.341 
16.882 
22.833 
26.095 
* Hydrolysis constants for SnIV were obtainedfrom literature [2] and included in 
the model. 
4.3.1 Proton dissociation constants 
In the protonation curve for PEI-MP, ZH , the calculated function follows the 
experimental data very closely (Figure 4.3.1 (a)).!t can be deduced that no further 
protons are lost beyond pH 1 0 as the curves level off at zero towards the higher pH 
region. The analysis reveals that there are four sites of protonation (proton 
dissociation). The pKI 9.683 would be due to dissociation at an amine centre, and 
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the remaining three stability constants corresponds with the methylenephosphonated 
functional groups. A fifth stability constant with a value greater than pKl above can 
be expected [3] at an amine site, but would require excessively basic conditions to 
achieve dissociation. Note that the Z H tends toward 5, indicating the propensity for 
further protonation. A fifth protonation constant was excluded from this model, as it 
\vas only allowed at the expense of pKa4 (3.992), which resulted in a large Hamilton 
R-factor and standard deviations of all species, and furthermore, compromising the fit 
between the experimental data (points) and the calculated ZH curve (line) that could 
best be achieved in the region pH 2 to 4 (Figure 4.3.l(a)). Figure 4,3, i(b) shows the 
distribution of the protonated ligand (PEI-MP) species at the respective pHs. The 
proposed model shows the consecutive dissociation of the ligand's protons as the pH 
is gradually increased. 
5 
4 
3 
~ 2 
1 ' 
o· 
-, , 2 3 4 5 1:1 7 8 9 10 '1 12 
pH 
Figure 4.3. 1 (a). Experimental (points) and modelled (lines) protonation 
formation curves for PEI-MP, Three titrations are represented by (0) 1.25mA1 
PEI-MP and 12,5mM HC1;(D) 1.89m1\l PEl-.MP and 13,66mA1 HCl and (A) 
2,49mM PEI-MP and 12.59mM Hel, all titration against 50,24m,\,j NaOH in 
100,3nlJ\;f NaC/, All solutions were at 25°C and 150mM NaC/ or 150mM total 
ionic strength. 
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pH 
Figure 4.3.1(b). Species distribution cun'es jor the pr%nalion of PEI-MP at 
2ye and O.15MNaCl. 
IY 4.3.2 Sn -(PEI-MP) formation constants 
For the titrations of PEI-MP with Sn1V the Z curves (Figure -I.2.2(a) exhibit back-
fanning at high pH (and high free ligand concentration), which is indicative of the 
presence of hydroxide containing species. This can be further supported when 
studying the Q curves (Figure 4.3.2(b)) generated from PEI-MP- Sn lV titration data, 
in which the experimental curves lie predominantly above the n line beyond pH 4. 
Furthermore, the speciation distribution analysis results show that all complexes 
formed were, in fact, hydroxyl species, including the region below pH 4, with 
[Sn:::L(OHh]o being very prominent. This could be due to the hydrolysis of the SnIV, 
which is typically unavoidable in water, and especially at higher pH, rendering the 
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ESTA analysis results rather distorted. Contrary to what would typically be expected 
- that due to presence of binuclear species (M2L), the Z curve should be seen to levcl 
off at 0.5 but instead stops at 1, which is more consistent with ML type complexes. 
However, the existence of the binuclear complexes can be rationalized from the Q 
curves. 
The speciation model, at pH 7.4 - which is of special interest when considering in 
vivo (physiological conditions), shows the complex [Sn IV 2L(OH)5] I to be dominant 
(60%), where L PEI-MP. Two other species are also present. namely 
[Snlv2L(OH)4]o (37%), and [Snlv2L(OHh]l+ (3%). Note that the formal charge of the 
ligand is negative 4, [Lt. Because of the instant formation of the hydrolysed 
species - [SnlV 2 L(OH)3] I at the start of the titrations, comprising close to 100% 
(Figure 4.3.2(c), little or no free metal \vas available for an equilibrium to exist. 
Hence the equilibrium constant for this species is inaccurate and practically 
unresolved within this experiment - as is evident from the high standard deviation. 
The model was refined as best possible including the M2L(OHh species ignoring all 
significant correlations after which the formation constant for this species was kept 
fixed for further analysis of the other constants. 
Upon coordinating with the Sn lV -ion(s), PEI-.\!lP exhibits the loss of one more proton 
than expected. This could be due to deprotonation at an amine centre, or from a 
metal-coordinated water molecule in which case we'd expect the formation constant 
of the MLOH species to be of similar magnitude than that of the first hydrolysis 
constant of SnlV (log KIO- 1 -1.94). This is not immediately evident from the model. 
However, having observed the dissociation constant for an amine site in the ligand-
protonation model (Table 1), pKaj 9.68, it is evident that upon interacting with the 
Snl\'-ion(s) the formation constants log K21 -5 = -9.25 and log K21 -7 -9.00, are close 
enough to assume that the metal-ion(s) coordinate at an amine centre resulting in the 
dissociation of a proton. 
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IN 1.5 
1.0 
0.5 
0.0 0 
o 2 4 6 8 10 12 14 16 18 20 22 24 
pA 
Figure 4.3.2(a). Experimental (points) and rnodelled (lines) for Z curves for PEI-MP 
complexation vl'ith SnlV Five titrations are represented by (0) O.30mM Snfl. 0.30mM 
PEI-MP and 728mM Hel; (Q O.NmA! Snfl. O.29mlv! PEI-lv!P and 708mM Hel: 
(..1)0. 14mM Sn /l • 0.43mlvf PEI-MP and 6. 97mJd HCl. (0)0 43nliV! Snll, O.29mM PEI-MP 
and 9.92mM Hel and (V)0.56mM Sn iV, 0.28m5M PEI-MP and 12.38mM Hel, all 
titration against 50. 02m 1M NaOH in 100mM NaC!. All solutions were at 25°C and 
150mM Nael or 1 50mM total ionic strength. 
12 
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Figure 4.3.2(b). Experimental (points) and modelled (lines) for Q curves for PEI-MP 
complexation with SnlV The dotted line represents the n curve, which is the 
protonation state of APDDMP in the absence of metal. Five tilrations are 
represented by (0) O.30mM Snll'~ 0.30mM PEI-MP and 728mM Hel: (QO.14mA! Sn l1 , 
If' O.29mAI PEI-MP and 708mM Hel; (..1)O.14mM Sn , O ..:f3mM PEI-MP and 6.97mM 
Hel: (O)O.:f3mM S,r, 0.29ml'v! PEI-MP and 9. 92mM Hel and (V)0.56mM S,r, O.28mM 
PEI-MP and 12. 38mM HCl, all titration against 5002mM NaOH in lOOmM NaC!. All 
solutions were at 25°C and 150mA! NaCI or 1 50mA! total ionic strength. 
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Figure 4.3.2(c). Species distribution curves for the complexation of PEJ-MP 
with Snll ' at 25°C and O,15M NaC!. 
Due to its nature as a polymer, some steric constraints can be anticipated when 
considering the possible binding sites for metal-ions in solution. Upon coordination the 
ligand can be expected to wrap around the Snlv-ion(s) effectively shielding the metal-
ion(s) from the aqueous environment, thereby limiting hydrolysis. There are essentially 
two methylene-phosphonate sites for metal coordination per PEI-MP sub-unit, with the 
likelihood of amine interactions at each. Various possible structures exist for SnlY -PEI-
MP complexes. PEI-MP has the potential to form multiple cyclic structures, which would 
contribute to the stability of these species. Examples of these are illustrated in Figures 
4.3.2 (d). (e) and (/). A common feature in all three structures proposed here is the 
chelation at the amine centres In conjunction with the neighbouring 
methylenephosphonate functional groups - resulting in the formation of stable 5-
membered rings. At one of the coordination sites a bicyclo[3,3,O]-structure could exist 
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(Figure 4.3.2(d)). A third ring is possible in this region, as the ligand wraps around the 
metal-ion to form a bicyclo[3,3,3]-species, as depicted in Figure 4.3.2(e). 
-0 O_~-O\ 0-
"I ~ / /p I R 
0/ ~....J'b 
*+N~N~* 
( /0 
~p o \-
o 
Figure 4.3.2(d). Proposed structure for a typical Sn::PEIMP complex. 
Illustrating two possible metal-binding sites. 
o 
o II 
" -P---o ~'" ) 
N'ln* 
.~ 
G~ ~ 0 rl-P-f I \ N-~--O < /'0 
-:;::-P 
o '0 
Figure 4.3.2(e). Proposed structure for a Sn::PEfMP !:Jpecies. Illustrating 
the ability of the P EI-MP ligand to wrap around the metal-ion forming a 
bicyclo[3,3,3J-structure. 
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The wrapping action of the ligand includes the possible coordination at the amine centre 
present in main chain of the polymer. An alternative structure - also considering the 
possible wrapping around and coordination of the same amine centre - could be to form 
two bicyclo[3,3,O] entities at the opposite ends of the polymer sub-unit (FiKure -1.3.2(/)). 
-0" /0 ,~-O\ /0 
/P I P o/v~~ 
CN~* ~··O N \ 
V ~\\O 
*11. ° 
Figure 4.3.2(j). Proposed structure for a Sn]P EI-A1P species. lllustratinK 
the ability of the PEl-ivfP ligand to wrap around the metal-ion forming 
two bicyclo[3, 3, OJ moieties. 
PEI-MP has the ability to form reasonably stable complexes, with some interesting 
coordination possibilities. NMR-spectroscopic techniques, such as NMR-titrimetry, will 
render more accurate predictions of these structures, and could lead to the enhanced 
understanding of their possible action within biological systems. However, this was 
outside the scope of these experiments, but could form the bases of future work. 
4.4 Conclusion 
The analyses of titration data for the protonation experiments reveal that PEI-MP 
possesses four dissociable protons, with successIve protonation at the 
methylenephosphonate sites, followed by the amine. Further dissociation would be 
possible at another amine site, should higher pH's be obtainable, or observable. The 
titrations conducted with Sn lV revealed the exclusive formation of hydrolysed complexes, 
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as confirmed in the Z and Q curves. The Sn lV complexes were binuclear i.e. of the type 
M2L (two metal centres were present). The Sn1v_PEI_MP species distribution was as 
follows: [Snlv2L(OH)xr- (x = 3, 4, 5, 6, 7; and y = 1, 0, 1, 2, 3 respectively, and L = 
PEI-MP). The anticipated hydrolysis of Sn lY also featured strongly at pH beyond 10, with 
[Sn 1v(OH)6f- being observed. At pH 7.4, which is of physiological significance, the 
following complexes occur (with their respective percentage mole fraction composition 
in parenthesis): 
• [Snlv2L(OH)s( (60%), 
• [SnIY2L(OH)4]o (37%), 
• [Snlv2L(OH)6f (3%). 
Various attempts at different models were fruitless in lovvering the unceltainties of the 
individual species, as well as the Hamilton R-factor. The model presented aboye was the 
most sensible that could be derived and refined. The species distribution at pH 7.4 shows 
that 60% of the metal is in the, [Snlv2L(OH)5]'- complex. Hence, under physiological 
conditions within blood plasma, SnlY -PEI-MP complexes are more likely to exist in the 
form M2L(OH)s. This could prove beneficial as a more directed action could be expected 
of the radiopharmaceutical when administered intravenously, reducing unwanted side-
etTects. 
Sn lV is readily hydrolysed in solution and forms a precipitate, making glass electrode 
potentiometric analysis and evaluation by EST A rather challenging. The method can be 
modified to counteract the precipitation by conducting titrations at static pH whilst 
titrating with an aqueous solution of SnlY (0.005M SnCl4 in 0.1 M HCI). This can be 
achieved by incorporating a second burette (0.05M NaOH in 0.1 M NaCI) for maintaining 
the pH. This method was attempted with the SnlY -PEI-MP experiments, but with no 
success. The technique will have to be fine-tuned and could prove beneficial for use with 
other experiments or systems with similar complications such as precipitation. PEI-MP 
forms very stable complexes with Sn lV such that at at low pH the complex was almost 
100% formed .. Better data could possibly be obtained by using a second ligand, which 
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could compete with PEI-MP. In this case the stability of the PEI-MP complexes would 
be determined relative to the new ligand .. For example, EDTA (ethylenediamintetraacetic 
acid) could be a likely candidate. 
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CHAPTER 5 
RATIONALISING THE HIGH KIDNEY UPTAKE OF 117mSnll_APDDMP IN RATS 
BY BLOOD PLASMA MODELLING USING ECCLES 
5.1 Introduction 
As part of a study to understand the bio-distribution of 117mSnll_APDDMP in the body, 
tests were conducted on rats [I]. With a potential appl ication in the diagnosis and 
treatment of metastatic hone cancer, the extent to which APDDMP localizes in bone 
relative to the rest of the body tissue was the objective of the study. In principle the 
radioactive 117mSnll is released at the point of uptake of APDDMP by bone, exchanging 
the Sn II for Call (in bone tissue). Effectively, y-Ray images taken of the subject wi!l make 
it possible to locate regions of high Call concentration, which is typical of bone tumours. 
However, images obtained of the rats revealed that most of the 117mSnll was located in 
the kidneys [1] for the 4 hour duration of the experiment. This was consistent with earlier 
studies found in literature [2], of tin-based radiopharmaceuticals (including Sn-chlorides 
for both oxidation state: 2+ and 4+), which exhibited rapid initial clearance of 117mSnll 
within the first 3 hours after injection. In order to unravel this phenomenon three 
hypotheses were presented: 
(i) The first of which was to assume that APDDMP clears faster with respect to 
117mSnlI, i.e. competition for APDDMP by other metal ions in blood plasma is 
greater. 
Oi) The second assumption was that the 117mSnll clears faster with respect to 
APDDMP, meaning that the body flushes out the 117mSnIl faster than the 117mSnll_ 
APDDMP complex can reach the bone tissue - i.e. competition for tin by other 
ligands in the blood plasma is too great. 
(iii) Thirdly it was assumed that the entire 117mSnIl_APDDMP complex clears too 
rapidly for the APDDMP to reach the bone tissue. This would be typically 
expected of highly charged complexes, as those formed by APDDMP and Snll 
(Chapter 2). 
61 
Un
ive
rsi
ty 
of 
Ca
pe
 To
wn
BLOOD PLASMA MODELLING OF! \7\lSn ll-APDDMP CHAfYl'ER 5 
These postulates were investigated usmg the blood plasma modelling programme 
ECCLES. 
5.2 Procedure 
The ECCLES programme was used to model the behaviour of Sn ll (M) and APDDMP 
(L) respectively in blood plasma relative to changes made to their concentrations. 
The three hypotheses were studied as follows: 
(i) By keeping the concentration of Sn ll constant the ratio of APDDMP to Sn ll was 
gradually reduced by lowering the APDDMP concentration, 
(ii) maintaining a constant concentration of APDDMP the L:M ratio was increased by 
changing the SnIl concentration, 
(iii) fixing the L:M ratio, the concentrations of both the APDDMP and Sn ll were 
lowered gradually. 
The ECCLES database had been updated to include formation constants measured for all 
species that Sn" formed with ligands (low molecular weight ligands, L WL) occurring in 
blood plasma [3], including Sn ll hydrolysis constants [4]. 
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5.3 Results 
5.3.1 First hypothesis 
Table 5.3.1: Hypothesis One, APDDMP clears rapidly relative to Snll Representing the 
percentages of the total Sn ff and APDDA1P concentrations that are bound according to 
the Sn1!-APDDlvlP species, 
MODEL: Keep Sn(lI) constant, decreasing the APDDMP 
Decreasing the L: M ratio 
(UM) 10 7.5 5 2.5 1 n 71;. 0.5 0.25 0.1 
MLH/!\lLDH 1 M: to LIM: 7.5 L 1 M: 5.0 L 1 M: 2.5 L 1M: LOL 1 M: 0.751. 1 M: 0.5 L 1 M: 0.25 L 1 M: 0.1 L 
Sn(lI) ~2.65E-05 2. 65E-05 2. 65E-05 2.65E-05 2. 65E-05 2.65E-05 2. 65E-05 2. 65E-05 
21-1 35.3 0 32.9% 29.2% 22.2% 13.4% 11.0% 8.2% 4.6% 2.0% 
21-2 18.0% 16.8% 14.9% 11.3% 6.8% 5.6% 4.2% 2.4% 1.0% 
110 4.7% 4.0% 3.0% 1.8% 0.9% 0.7% 0.5% 0.3% 0.1% 
210 1.1% 1.0% 0.9% 0.7% 0,4% ~ 0.3% 0.1% 0.1% 11-1 0.2% 0.2% 0.1% 0.1% 0.0% 0.0% 0.0% 0.0% 
21-3 0.1% 0.1% 0.1% 0.1% 0.0% 0.0% 0.0% 0.0% 
Total % .0% 48.2% 36.2% 21.5% 17.7% 13.2% 7,4% 3.2% 
APDDMP 2.65E-04 1.99E-04 1.33E-04 6. 63E-05 2. 65E-05 1.99E-05 1.33E-05 6. BlE-06 2.65506 
21-1 1.8% 2.2% 2.9% 4.4% 6.7% 7.3% 8.2% 9.2% 10.0% 
21-2 0.9% 1.1% 1.5% 2.3% 3.4% 3.7% 4.2% 4.7% 5.1% 
110 0.5% 0.5% 0.6% 0.7% 0.9% D.!=!% 1.0% 1.0% 1.1% 
210 0.1% 0.1% 0.1% 0.1% 0.2% o~~=r 0.3% 0.3% 11-1 0.0%=±10% 0.0% 0.0% 0.0% 0.0 .0% 0.0% 0.0% 21-3 0.0% .0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 
211 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 
21-4 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 
Total % 3.3% 3.9% 5.1% 7.5% 11.2% 12.1% 13.7% 15.2% 16.5% 
Total Concetrations comp/exed 
[5n(lI)) 1.S7E- 5 1.28E-05 9.59E-06 5.70E-06 4.69E-06 3.50E-06 1. 96E-06 8,48E-07 
[APDDMP] 8.7SE-06 7.7SE-06 6.76E-06 4.97E-06 2.97E-06 2.40E-06 1.82E-06 1.01E-06 4.37E-07 
(UM) 0.56 0.53 0.53 0.52 0.52 0.51 0.52 0.51 0.52 
By gradually decreasing the ratio of APDDMP:Sn li in ECCLES the species distribution 
of both the metal and ligand can be monitored according to their individual complexes, as 
depicted in Table 5.3.1 above. This serves mainly to monitor any changes in the species 
composition with respect to ligand concentration. By lowering the concentration of 
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APDDMP in blood, the percentage of the total Sn ll that binds with the ligand also 
decreases (Figure 5.3.1 c). For the individual species the same trend can be observed 
(Figure 5.3.1a). However, the extent/rate of decrease in the amount of Sn ll that occurs 
within the complexes is greater for the more dominant species. The minor species exhibit 
a rather steady decline in their composition of Sn ll as the APDDMP concentration IS 
lowered. 
The relative affinity for complexation between APDDMP and Sn ll (considered in terms 
of the ratio of complexation, Figure 5.3. J e) remains unchanged as the ligand 
concentration decreases, i.e. for every mole of APDDMP there are approximately 2 moles 
of Sn ll that readily interact to form complexes, and as the total concentration of 
APDDMP is lowered the amount of Sn ll that will complex also decreases accordingly 
(Figure 5.3. Jd). This is observed when APDDMP is administered in excess as well as 
when the concentration is below that of Sn ll . Essentially, this means that any excess 
APDDMP is taken up by in vivo metal-ions, and hence decreasing the adiministered 
concentration would mean that the only alternative source of APDDMP is from Sn ll -
APDDMP complexes. Therefore, for any decrease in APDDMP, a relative amount of SnIt 
will be released so as to maintain the ratio (L:M) of complexation. Should the lowering of 
the amount APDDMP in blood plasma have not atTected the SnIl-APDDMP complexes, 
the amounts (concentrations) of complexed metal and ligand would have remained the 
same throughout. However, still resulting in a constant rlttio of complexation, but only 
until the excess has been depleted, whereupon the results will resemble the above 
experiment (Table 5.3.1). Figure 5.3.1 b shows that APDDMP complexation with Sn ll is 
constant, and changes in the available ligand concentration (total) has little or no effect -
the influence is mathematical, increasing the percentage of APDDMP that is bound to 
Sn ll mainly due to lowering of the total concentration. In order to prove that renal 
clearance is mainly due to the ligand, the expected result should've been a decrease in the 
ratio of complexation by infinitesimally decrementing the APDDMP concentration. 
In reality, this scenario would describe the removal of APDDMP by possible competition 
of physiological metal-ions with the tendency to form more favourable/stable complexes. 
64 
Un
ive
rsi
ty 
of 
Ca
pe
 To
wn
BLOOD PLASMA MODELLING OF 117MSnli_APDDMP CHAPTER 5 
It would be expected that the least stable Sn"-APDDMP complexes would be influenced 
to a larger extent. However, what is observed is a faster decrease within the dominant 
species, which comprises a larger proportion of the Sn"-ion content. 
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Figure 5.3.i(a): Model ONE: APDDMP clears rapidly w.r.t. Sn". Percentage Sn ll 
that complexed with AP DDMP verses Ratio administered Lines represent the 
best-fit trend curvesljunctions. 
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It would be expected that the least stable Snll-APDDMP complexes would be influenced 
to a larger extent. However, what is observed is a faster decrease within the dominant 
species, which comprises a larger proportion of the Snll-ion content. 
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Figure S.3.i(a): Model ONE: APDDMP clears rapidly w.r.t. Sn". Percentage Sn" 
that complexed with AP DDMP verses Ratio administered Lines represent the 
best-fit trend curveslfimctions. 
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Figure 5.3.1(b) : Model ONE: APDDMP clears rapidly w.r.t. Snll Percentage APDDMP 
that complexed with Sn" verses Ratio administered. Lines represent the best-fit trend 
curveslfunctions. 
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Figure S.3.I(e) : Changes observed in the amounts (%) ojSn" and APDDMP that 
remain complexed in vivo, as the administered ratio LM is decreased (i.e. by 
gradually lowering the amount oj APDDMP administered relative to Sn/~ . 
• Percentage ojSn" that remains complexed; Il percentage oj APDDMP that 
remains complexed. Lines represent the best-fit trend curvesljunctions. 
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Figure 5.3.1(d): Change in total concentrations that are complexed uS the administered 
ratio L:M is decreased (i.e . by gradually lowering the amount of APDDMP administered 
relative to Sn ll). I Total concentration of Sn ll that remains complexed; _ total 
concentration of APDDMP that remains complexed. Lines represent the best-fit trend 
curvesljimctions. 
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Figure S.3.I(e): Changes in (UM) ratio of complexed APDDMP and SN" as the 
administered (UM) ratio is lowered. Trend in the ratio of APDDMP:Sn ll that remains 
complexed in the blood plasma as the ratio that is administered is decreased. I Ratio of 
in vivo complexation. Lines represent the best-fit trend curvesljunctions. 
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5.3.2 Second hypothesis 
Table 5.3.2: Hypothesis 2; Sn" clears rapidly relative to APDDMP. Representing the 
percentages of the total Sn" and APDDMP concentrations that are bound according to 
the Sn"-APDDMP species. 
MODEL: Keep APDDMP constant, decreasing Sn(ll) 
Increasing the L:M ratio 
'ILML 10 15 20 25 30 35 40 45 50 
MLH/MLOH 1M: tOL 1M: 15 L 1 M : 20 L 1M: 25 L 1 M : 30 L 1 M : 35 L 1 M : 40 L 1 M: 45 L 1M: 50 L 
5n(lI) 2. 65E-05 1. 77E-05 1.33E-05 1.06E-05 8. 83E-06 7.57E-06 6. 63E-06 5. 89E-06 5.30E-06 
21-1 35.3% 30.8% 27.6% 25.0% 22.9% 21 .2% 19.8% 18.5% 17.4% 
21-2 18.0% 15.7% 14.1% 12.8% 11 .7% 10.8% 10.1% 9.5% 8.9% 
110 4.7% 5.5% 6.0% 6.4% 6.7% 7.0% 7.2% 7.4% 7.6% 
210 1.1% 1.0% 0.9% 0.8% 0.7% 0.7% 0.6% 0.6% 0.6% 
11-1 0.2% 0.2% 0.3% 0.3% 0.3% 0.3% 0.3% 0.3% 0.3% 
21-3 0.1% 0.1% 0.1% 0.1% 0.1% 0.1% 0.1% 0.1% 0.1% 
Total % 59.4% 53.3% 49.0% 45.4% 42.4% 40.1% 38.1% 36.4% 34.9% 
APDDMP 2. 65E-04 2. 65E-04 2. 65E-04 2. 65E-04 2. 65E-04 2. 65E-04 2.65E-04 2. 65E-04 2. 65E-04 
21-1 1.8% 1.0% 0.7% 0.5% 0.4% 0.3% 0.2% 0.2% 0.2% 
21-2 0.9% 0.5% 0.4% 0.3% 0.2% 0.2% 0.1% 0.1% 0.1% 
110 0.5% 0.4% 0.3% 0.3% 0.2% 0.2% 0.2% 0.2% 0.2% 
210 0.1% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 
11-1 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 
21-3 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 
211 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 
21-4 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 
Total % 3.3% 1.9% 1.4% 1.1% 0.8% 0.7% 0.5% 0.5% 0.5% 
Total Concetrations comf}jexed 
[5n(lI)] 1.57E-05 9.42E-06 6.49E-06 4.81E-06 3.75E-06 3.04E-06 2.52E-06 2.14E-06 1.85E-06 
[APDDMP] 8.75E-06 5.04E-OS 3.71 E-06 2.92E-06 2.12E-06 1.86E-06 1.33E-06 1.33E-06 1.33E-06 
(UM) 0.56 0.53 0.57 O.Sl 0.57 0.61 0.52 0.62 0.72 
In order to elucidate whether the main cause for renal clearance is due to dissociation of 
the metal-ion from the complex is, the SnlI concentration can be varied to study the trends 
in the complexation behaviour of the individual species (Table 5.3.1). The amount of SnlI 
introduced was gradually decreased to eventually allow for a large excess of the ligand. 
Initially there is a sharp decrease in the amount of APDDMP that binds with SOli, but 
beyond the L:M excess of 35 the percentage of the total ligand concentration that forms 
complexes with tin remains constant (Figure 5.3.2c) - as is also observed for the 
70 
Un
ive
rsi
ty 
of 
Ca
pe
 To
wn
BLOOD PLASMA MODELLING OF '17MSnJl_APDDMP CHAPTER 5 
individual Sn"-APDDMP species (Figure 5.3 .2b). When considering the changes in the 
amount of Snl! that occur in the individual Sn"-APDDMP complexes, only the prominent 
species are affected. In the composition of the hydrolysed complexes a decline in the 
percentage of the total Sn" concentration is evident, whereas for the non-hydrolysed 
species the inverse is observed - indicating an increased preference for their formation as 
the amount of Sn" that is administered is lowered (Figure 5.3 .2a). 
The total amounts of both the metal and ligand that form Sn"-APDDMP complexes 
decrease rapidly as the concentration of Sn ll in blood plasma in lowered (Figure 5.3 .2d). 
If renal clearance was not caused by rapid removal of Sn ll from Sn"-APDDMP 
complexes, then any change in the metal concentration would keep the amount of ligand 
that complexes per Sn"-ions (ratio of complexation, L:M) constant - i.e. observing a 
stoichiometric decrease in the percentage of APDDMP that bind with tin . However, 
Figure 5.3 .2e indicates that the complexation ratio increases as the tin concentration 
decreases, implying that the survival of the Sn"-APDDMP complexes within blood 
plasma is dependent on Sn" affinity for APDDMP. 
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Figure 5.32(a): Model TWO: Sn ll clears rapidly w.r.t. APDDMP. Percentage Sn" that 
complexed with APDDMP verses Ratio administered. Lines represent the best-fit trend 
curves/functions. 
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Figure S.3.2(c): Changes in the percentages of Sn lJ and APDDMP that are complexed in 
the bloud plasma as the administered ratio APDDMP.Sn" in increased by gradually 
I . h SII . owermg ten concentratIOn. I Percentage of Sn ll that remains complexed; _ 
percentage of AP DDMP that remains complexed. Lines represent the bestjit trend 
curvesljunctions. 
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Figure 5.3.2(d): Changes in the total concentrations that are complexed in the blood 
plasma as the administered ratio AP DDMP:Sn" in increased by gradually lowering the 
Sn" concentration. ITotal concentration of Sn" that remains complexed: Ii total 
concentration of APDDMP that remains complexed. Lines represent the best-fit trend 
curvesljunctions. 
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Figure 5.3.2(e): Changes in the ratio (LIM) for complexed Sn" and AP DDMP, as the 
administered ratio is increased (Sn"). Trend in the ratio of APDDMP:Sn" that is 
complexed in the blood plasma as observed when the administered ratio is increased. 
I Ratio of in vivo complexation. Lines represent the best-fit trend curves/functions. 
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5.3.3 Third hypothesis 
Table 5.3.3: Hypothesis 3; Snll-APDDMP complexes clear rapidly. Representing the 
percentages of the total Snll and APDDMP concentrations that are bound according to 
the Sn"-APDDMP species. 
MODEL: Keep L:M ratio constant, decreasin the SnUll and APDDMP concentrations 
MLH/MLOH 1 M: 10 L IM:lOL IM : lOL 1 M: 10 L 1 M: 10 L 1 M : 10 L 1 M : 10 L IM:lOL 1 M: 10 L 
5n(lI) 2. 65E-05 1. 99E-05 1.33E-05 6. 63E-06 2. 65E-06 1. 99E-06 1.33E-06 6. 63E-07 2. 65E-07 
21-1 35.3% 29.7% 21 .3% 9.1% 1.9% 1.1% 0.5% 0.1% 0.0% 
21-2 1B.0% 15.1% 10.9% 4.6% 1.0% 0.6% 0.3% 0.1 % 0.0% 
110 4.7% 4.4% 3.7% 2.4% 1.1% O.B% 0.6% 0.3% 0.1% 
210 1.1% 0.9% 0.7% 0.3% 0.1% 0.0% 0.0% 0.0% 0.0% 
11-1 0.2% 0.2% 0.2% 0.1% 0.0% 0.0% 0.0% 0.0% 0.0% 
21-3 0.1 % 0.1% 0.1% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 
Total % 59.4% 50.4% 36.9% 16.5% 4.1% 2.5% 1.4% 0.5% 0.1% 
APDDMP 2. 65E-04 1. 99E-04 1.33E-04 6. 63E-05 2. 65E-05 1. 99E-05 1.33E-05 6. 63E-06 2. 65E-06 
21-1 1.B% 1.5% 1.1% 0.5% 0.1% 0.1% 0.0% 0.0% 0.0% 
21-2 0.9% O.B% 0.5% 0.2% 0.0% 0.0% 0.0% 0.0% 0.0% 
110 0.5% 0.4% 0.4% 0.2% 0.1% 0.1% 0.1% 0.0% 0.0% 
210 0.1% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 
11-1 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 
21 -3 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 
211 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 
21-4 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 
Total % 3.3% 2.7% 2.0% 0.9% 0.2% 0.2% 0.1% 0.0% 0.0% 
Total Concetrations comp/exed 
[Sn(ll)] 1.57E-05 1.00E-05 4.91 E-06 1.09E-06 1.09E-07 4.9BE-OB 1.B6E-OB 3.32E-09 2.65E-10 
[APDDMP] B.75E-06 5.37E-06 2.66E-06 5.97E-07 5.30E-OB 3.9BE-OB 1.33E-OB O.OOE+OO O.OOE+OO 
(UM) 0.56 0.54 0.54 0.55 0.49 O.BO 0.71 0.00 0.00 
Provided that the ratio of ligand to metal that is introduced into blood plasma is 
maintained , the extent of complexation between the Sn" and APDDMP should effectively 
remain constant for any variation in their administered concentrations. Similarly, should 
there be rapid clearance of the entire Sn"-APDDMP from the body the ratio of 
complexation should remain unchanged. This was tested by slowly decreasing both the 
Sn" and APDDMP concentrations within blood plasma, whilst keeping the ligand to 
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metal ratio fixed (Table 5.3.3). The ratio of the amounts of APDDMP to Sn" that formed 
complexes varied, with a general trend to increase as the concentrations were decreased 
(Figure 5.3.3e). Figures 5.3.3c and 5.3.3d reveal that the amount/percentage of Sn"-ions 
that remains complexed to APDDMP decreases more rapidly than that of the ligand, 
which could serve to confirm the second postulate which states that the renal clearance is 
mainly due to dissociation of Sn ll . 
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Figure 5.3.3(a): Model THREE: SnIl-APDDMP clears rapidly. Percentage Sn ll 
that complexed with APDDMP verses concentration administered. Lines 
represent the best-fit trend curvesljunctions. 
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Figure 5.3.3(b) : Model THREE: Sn"-APDDMP clears rapidly. Percentage APDDMP 
that complexed with Sn" verses concentration administered Lines represent the best-fit 
trend curvesljunctions_ 
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Figure 5.3.3(c): Changes observed in the amounts (%) of Sn" and APDDMP that remain 
complexed in vivo, as the concentrations of each is gradually lowered (muintaining a 
fixed administered ratio LM)). I Percentage of Sn" that remains complexed,- Ii 
percentage of APDDMP that remains complexed. Lines represent the best-fit trend 
curveslfunctions. 
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Figure 5.3.3(d): Changes observed in the total concentrations of Sn" and APDDMP that 
remain complexed in vivo, as the concentrations of each is gradually lowered 
(maintaining a fixed administered ratio L:M)). I Total concentration of Sn" that 
remains complexed; _ total concentration of APDDMP that remains complexed. Lines 
represent the best-jit trend curveslfunctions. 
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Figure 5.3.3(e): Changes in ratio (LIM) for complexed Sn" and APDDMP, as the 
administered concentrations of both Sn and APDDMP decreases. Trend in the ratio of 
APDDlvfP:Sn" that is complexed in the blood plasma as observed when the administered 
concentrations of both SnIl and AP DDMP are decreased simultaneously. I Ratio of in 
vivo complexation. Lines represent the best-fillrend curves/functions. 
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5.4 Discussion 
5.4.1 Blood plasma modeling of SnII-APDDMP at clinical 
concentrations 
Radiopharmaceuticals are usually administered intravenously, with the ligand (L) in large 
excess, typically in order of 10: 1 (LM). During animal trials the concentrations of the 
drug depend on the type of animal being used. The radiopharmaceutical is injected into 
larger animals such as baboons (primates) with a metal (M) concentration of 
8.5xl0-6 mol.dm-3 and a ligand concentration of 8.5 x l0-5 mol.dm -3 . In studies with rats 
(rodents) concentrations of [M] = 2.65 x 10-5 mol.dm -3 and [L] = 2.65 x 10-4 mol.dm -3 
were used [1]. These concentrations were adopted in the investigation of the rodent blood 
plasma model using ECCLES. The preferred clinical doses for injecting the 
radiopharmaceutical 117mSnIl_APDDMP in patients (human) is similar to that of primate 
studies, with [M] = 8.5 x 10-5 mol.dm-3 , and [L] = 8.5 x 10-4 mol.dm -3 . Blood plasma was 
modelled with these concentrations for Sn ll and Apddmp and their speciation observed 
(Figures 5.4.1a and 5.4.1b) . 
Calcium (Ca") forms very stable complexes with APDDMP, readily displacing the Sn" 
into the blood plasma where it reacts with physiologically occurring ligands. This is 
evident in the speciation diagrams. Almost all (95.) %) of the APDDMP is taken up by 
Calf (Figure 5.4.1 b): Ca2(APDDMP) (66.8%), Ca2(APDDMP)OH (24.1%), and 
Ca2(APDDMP)H (4.2%). Only 0.1 % of the total APDDMP concentration in blood 
plasma is bound to Sn", with a remaining 4.7% being attributed to complexation with 
Mgf[: Mg2(APDDMP)OH (2 .2%), Mg2(APDDMP) (2.0%), and Mg2(APDDMP)H 
(0.5%) . 
A considerable proportion of the Sn" undergoes hydrolysis, Sn(OH)2 (37.9%) and 
Sn(OH)3 (0.4%), whilst most of the remaining tin binds with the ligands found in blood 
plasma upon dissociation from the complex(es). The most prominent species being that of 
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histinidinate, (Sn(His)OH) 35.5% and Sn(His) 2.8%, and cysteinate (Sn(Cys)) 11.7%. 
The distribution of Sn ll is rather extensive (Figure 5.4. J a), with interactions of 17 blood 
plasma ligands, and a considerable amount of these being binary complexes. In total, only 
about 2.8% of Sn ll remams bound by Apddmp: Sn2(Apddmp)OH (1.8%), 
Sn2(Apddmp)(OH)2 (0.9%), and Sn2(Apddmp) (0.1 %). The vast distribution of Sn ll can 
be mainly attributed to the high affinity of the ligand (APDDMP) for Ca". 
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Figure 5.4.1a: Speciation ofSn" in normal blood plasma at preferred clinical doses, [MJ 
= 8.5xI0-5 mol.dm-3 and[LJ = 8.5x10-4 mol.dm-3 , 
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Figure 5.4.1b: Speciation of Apddmp in normal blood plasma at preferred 
clinical doses, [M) = 8.5 x 10-5 mol.dm -1 and [L} = 8.5 xl 0-4 mol.dm-3 . 
In Figure 5.4.1a the species defined as "other" are comprised of all complexes which 
individually account for 0.1 % of Sn" within blood plasma. These include: 
Sn(Cys)(Phe); Sn(Cys)(Leu); Sn(Cys)(Asp); Sn(Cys)(Arg); Sn(Cys)(Pro); Sn(Gln)(Gly); 
Sn(Gln)(Ser); Sn(Cys)(Cta); Sn(Gly); Sn(Gln)OH; Sn(Gly)(Thr); Sn(Asn)OH; 
Sn(Ser)(Thr); Sn(Val)(Gln); Sn(Asn)(Gln); Sn(C03)H; Sn(Cys)(Mla); Sn(Thr)(Val); 
Sn(Thr)(Asn). 
• Abbreviations for FiJ;ures 5.4.1 a and 5.4.1 b: 
Arg: Arginine; Asn: Asparaginate; Asp: Aspartate; 
Cys: Cysteinate; Cis: Cystinate; Gin: Glutaminate; 
Gly: Glycinate; His: Histidinate; Leu: Leucinate; 
Phe: Phenylalanate; Pro: Prolinate; Ser: Serinate; 
Thr: Threoninate; Val: Valinate; C03: Carbonate; 
Cta : Citrate; Mia: Malate. 
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Figure 5.4.1c: Plasma mobilisation index curves for Apddmp. The arrow 
represents a probable ligand concentration used for administering the drug in 
patients: [LJ = 8.5xlO-5 mol.dm-3 . 
The blood plasma mobilisation index (P.M.I.) curves (Figure 5.4.1c) illustrate the extent 
to which the ligand, APDDMP, influences the natural balance of parti cu lar metal-ions 
within the blood plasma. The P.M.!. curves give an indication as to whether it would be 
necessary to provide the patient with mineral supplements so as to compensate for the 
mobilisation effect of the ligand (APDDMP). The arrow denotes the ligand concentration 
which would be used in the clinical administration of the radiopharmaceutical. Only Ca ll -
ions are mobilised by APDDMP at a concentration of 8.5 x 10-5 mol.dm -3 . Due to the 
abundance of Ca" within the body, the overall effect is buffered. Hence the observed 
mobilisation appears to be minor. 
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5.4.2 Rationalisation of hypotheses 
If APDDMP clears faster with respect to Sn" (according to the first postulate) the ratio of 
APDDMP to Sn ll that remains (complexed) in the blood plasma would decrease as the 
amount of APDDMP is lowered. Therefore, by decreasing the ratio of the "administered 
dose", the in vivo ratio of Sn ll and APDDMP that remains complexed would also 
decrease. A constant "complexation ratio" would indicate an independence of APDDMP 
concentration solely. Meaning that only a limited amount of Snll readily form complexes 
with APDDMP in blood plasma. The remaining tin was either substituted by other metal 
ions upon which it was flushed out via the kidneys, or the Sn ll was "hijacked" by other 
ligands in the blood plasma and then flushed out. 
Faster clearance of the Sn ll relative to APDDMP would result in an increase in the 
APDDMP:Sn ll ratio of complexation. An increase in the ratio that is administered - by 
gradually decreasing the concentration of Sn ll - should then result in an increase in the 
ratio of APDDMP and Snll that stays complexed in the blood plasma. As above, a 
constant complexation ratio could mean that Sn ll is the limiting component and as a result 
no more APDDMP will complex with tin than the tin will allow. 
Should the Snll-APDDMP complexes, as a whole, clear too rapidly for any worthwhile 
interaction with bone tissue to occur, the ratio of complexation would then remain 
constant irrespective of any changes in the concentrations of either Sn ll or APDDMP, or 
both. For a constant ratio of the SnJl and APDDMP administered , a gradual decrease in 
the concentrations of APDDMP and Sn" respectively, would result in the ratio of 
complexation being maintained. 
From Figure 5.3. J (c) it is evident that for a fixed amount Sn ll the percentage that 
complexes with APDDMP decreases as the amount of APDDMP decreases. This could 
be mainly due to other metal ions present in blood plasma competing for APDDMP, and 
forming more stable complexes than that of Sn". By decreasing the APDDMP 
concentration its ability to compensate for competition of the metal ions in reduced . The 
87 
Un
ive
rsi
ty 
of 
Ca
pe
 To
wn
BLOOD PLASMA MODELLING OF 117MSn"_APDDMP CHAPTER 5 
percentage APDDMP that form complexes with SnIl increases. This indicates that a fixed 
amount of APDDMP is available for complexation with Sn ll and that a change in the 
amount of APDDMP in the blood plasma has little effect, if any, on the extent of 
complexation. The LM ratio of complexation remains constant (y = I x I 0-16x + 0.52, R2 = 
0.96, where y is the complexed ratio and x the administered ratio) as the amount of 
APDDMP is lowered relative to SnIl (Figure 5.3.1 (e). Thereby, disproving the first 
hypothesis that APDDMP clears rapidly with respect to Sn". 
Maintaining a fixed amount of APDDMP while gradually decreasing the Sn" 
concentration resulted in a drop in the percentage of both Sn" and APDDMP that were 
complexed - Figure 5.3.2(c). The ' ratio of complexation ' increased as the 'administered 
ratio ' was increased (y = 0.0034x + 0.50, R2 = 0.73, where y is the ratio of complexation 
and x the administered ratio) (Figure 5.3.2(e)), indicating the likelihood that Sn" clears 
rapidly relative to APDDMP in blood plasma. 
As can be seen in Figure 5.3.3 (c), there is an increase in the percentage of both Sn II and 
APDDMP that are complexed as their concentrations are lowered while maintaining the 
'administered' ratio of I: 10. The complexation ratio increases (y = -0 .79x + 0.7, R2 = 
0.62, where y is the complexed ratio and x the administered ratio), rendering the third 
hypothesis false (Figure 5.3.3(e). The increase in the ratio of complexation could be 
attributed to the change in the concentration of Sn", thereby verifying the assumption that 
Sn" clears rapidly with respect to APDDMP. 
The bone seeking ability of phospho nates is well known as is their fast renal clearance. In 
order to evaluate this for APDDMP a study in a baboon was undertaken [5]. This non-
terminal experiment was carried out under protocol and due care was taken to ensure the 
well-being of the animal at all stages. One can monitor the biodistribution of the ligand 
by injecting 99mTc-labeled APDDMP, as conducted by Zeevuart et al [5]. Because no 
uptake of 99mTc in the thyroid was recorded (indications of free pertechnetate) it was 
assumed that the 99mTc stays bound to the polymer presenting an accurate biodistribution 
of APDDMP. The results, as presented in Figure 5.4.2(a), were corrected to the time of 
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injection for the radioactive decay of the 99mTc. From these experiments the rate of renal 
clearance of the ligand can be compared with that of its distribution in bone. There is a 
rapid accumulation of 99mTc_APDDMP in the kidneys within 4 minutes after injection, 
where the maximum renal concentration is reached (Figure S.4.2(b)). The spine uptake 
shows that within 2 minutes of injection the bone receives its maximum dose, after which 
slow and steady clearance is observed. 
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Figure 5.4.2(a). Biodistribution of 99mTc_APDDMP as observed in animal experiments 
[5]. Monitored as count per pixel for a duration of 4 hours, which included a 30 minute 
dynamic study followed by a static study up to 4 hours. (Where Card = cardiac blood 
pool; BG = backbround.) 
The rate of clearance can be defined as the time taken for the ligand concentration to be 
halved (I , ), which in the case of the kidneys was t1 = 10 minutes. Within the spine the 
, , 
concentration reached after 3 hours (which is the same as observed at 4 hours) is close to 
the expected half-concentration, therefore t 1 2 3 hours for bone. Hence, by comparison, 
, 
it is clear that the ligand is present at the target (bone) long after the initial rapid renal 
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clearance. Despite the relatively large amount of APDDMP that is passed via the kidneys 
there is still an acceptable accumulation of the ligand within bone. From the slow spinal 
clearance rate (t 1 ~ 3 hours) it is also safe to assume that, upon uptake at the bone 
1 
interface, most of the APDDMP remains favourably bound. 
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Figure 5.4.2(a}. Distribution and clearance of99mTc_AP DDMP within the spine and 
kidneys as observed in animal experiments [5]. Monitored as count per pixel for a 
duration of 4 hours, which included a 30 minute dynamic study followed by a static study 
up to 4 hours. 
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5.5 Conclusion 
In normal blood plasma only 0.1% of APDDMP remained complexed with SnIl. 
Furthermore, this 0.1% of APDDMP (i.e. complexed with Snll) accounts for only 2.8% of 
the total Sn ll in blood plasma (Figure 5.4.10). 95.1% of APDDMP was taken up by Call. 
Histidinate and cysteinate complexed about 38.3% and 11.7% of Sn ll respectively 
besides the binary complexes they've formed in combination with other ligands. Due to 
the extent of hydrolysis ofSn lf (38.3%), the dissociation of the Snll-APDDMP complex in 
blood plasma is mainly attributed to competition by Call, and to a smaller degree Mgll, for 
the APDDMP ligand. Thereby displacing the Snll ions into the blood plasma where it 
hydrolyses, as opposed to the scavenging of the SnIl ions by in vivo ligands. The tin-ions 
that are not immediately hydrolysed are then complexed by a variety of ligands resulting 
in a large distribution of Sn ll species within blood plasma. However, the plasma 
mobilisation effect of APDDMP which is only observed for Ca 11 - is negligible (Figure 
5.4.1c). 
The behaviour of Sn ll and APDDMP in blood plasma was best depicted by the second 
hypothesis - the Sn ll clears rapidly relative to APDDMP. The results of the first postulate 
- in which the rapid clearance of APPDMP with respect to SnIl was tested served to 
confirm the second hypothesis. 
The rationale behind the method used was to "starve" the complex of one of its 
components. The ligand is usually administered in excess in this instance with a metal-
to-ligand ratio of 1: 1 O. Because of the abundance of I igand available for complexation, 
any change made to the ligand concentration should not affect the extent of complexation 
to a large degree. However, this only stands if competition for SnIl by other ligands is 
negligible. This is proven by the first postulate, in that the percentage of comptexed 
[APDDMP] to the total concentration increases since the total ligand concentration is 
being lowered. This should still ensure the survival of the radiopharmaceutical for 
delivery at the target tumour, because of a fixed interaction between APDDMP and Sn ll . 
Hence, beyond the amount of APDDMP that was compensated for competition by other 
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ligands (i.e. the excess) the complex does not dissociate readily. Therefore, the SnIl does 
not favour complexation with physiologically occurring ligands over APDDMP. 
On the other hand, competition of a second kind must be tested, whereby the metal-ions 
in blood plasma compete against Sn ll for APDDMP. Upon injection the excess APDDMP 
binds to the physiological metal-ions, and further displaces the Snii ion from the complex. 
The effect would be similar to that of the second hypothesis, in which the ratio of SnlI-to-
APDDMP that remains complexed increases as the available [SnII] is decreased. 
Understandably, the percentage of the total SnIl concentration that is complexed 
decreases since its capacity to counteract the competition of other metal-ions is reduced. 
The drop in the percentage of [APDDMP] that remains complexed supports this the 
competition of the metal-ions outweighs the SnIl ion's chances of forming complexes. 
Rapid clearance of the entire complex would be mainly due to metabolism. The third 
assumption only confirmed predictions made above. Although both the Snit-ion and 
APDDMP concentrations are decreased there was sti II a clear increase in the ratio of 
complexation. Since it has been shown that the extent of complexation is independent of 
the [APDDMP], it stands to reason that the mere drop in the available SnIl ion 
concentration hinders its survival within the Snll-APDDMP complex. 
APDDMP's affinity for Call could be too high. Most likely the Sn ll ions are displaced by 
the Call ions present in blood plasma, adversely affecting delivery of the radionuclide to 
the bone tumour. Instead, the radioactive tin-117m (117mSnll) is flushed out via the 
kidneys in the form of histidinate and/or cysteinate complexes, accounting for more than 
50% of the Sn ll in the blood plasma. However, the APDDMP ligand could still continue 
the journey towards the tumour, but without the active ingredient I 17mSnII - and with Ca" 
ions instead - having been hijacked. Due to the extent of hydrolysis of Sn ll (about 40% of 
the tin(II)-ions) it would also be reasonable to expect to see considerable uptake by the 
liver or the reticuloendothelial system, as reported for studies conducted on Sn"-chloride 
by Srivastava et al (2]. Srivastava also noted the difficulty of working with tin-based 
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compounds at pH7.4, as the reproducibility of results was hampered by the ease at which 
tin hydrolyses (both SnIl and Sn'Y), as well as the ease of oxidation of Sn ll . 
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CONCLUSION AND FUTURE WORK 
6.1 Conclusion 
The conventional techniques for developing and evaluating radiopharmaceuticals 
involved the random selection of a metal-ion and I igand combination with the hope of a 
positive outcome. The method involved a series of extensive animal trials. By pooling the 
vast variety of analytical tools available for elucidating novel systems, the chances of 
making more educated predictions are enhanced as to the behaviour of prospective 
therapeutic agents, as illustrated in this thesis to a small degree. In this study glass 
electrode potentiometry was combined with a computer simulated model of blood plasma 
(ECCLES) to effectively evaluate the In VIVO behaviour of a potential 
radiopharmaceutical, SnJ1-APDDMP, thereby predicting the effectiveness of the drug 
without having to pursue animal experiments. The outcome of which can later be 
validated by a limited number of well-planned animal studies. 
Radioactive tin-117m (117mSn) was identified as a suitable nuclide because of its 
favourable radiation characteristics, affording low radiotoxicity to the more sensitive 
healthy bone marrow. This is favourable as it allows for an increase in the administered 
dose with minimal side-effects. Preliminary 'cold' experiments were conducted with 
stable forms of SnIl and SnlY for the potentiometric determination of the equilibria with 
the respective ligands of choice. 
Two fairly new phosphonate ligands were studied. as these are regarded as having good 
bone affinity, and hence expected to aid in the accumulation of the drug in regions of 
high bone-turnover - as is characteristic of tumours. The ligands being: N,N.-
dimethylenephosphonate-I-hydroxy-4-aminopropylidene-diph05phonate (AP DDMP) and 
N.N'.N'-trimethylenephosphonate-polyethyleneimine (PEI-lv/P). 
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The complexation equilibria that were observed were that of SnIl-APDDMP and Sn lV 
PEI-MP. Complexation studies of APDDMP with those metal-ions that occur in blood 
plasma in high concentration namely Call, Mgll and lnll were also studied. The analyses 
of titration data by ESTA produced satisfactory results, and reasonably low Hamilton R-
Factors and standard deviations. The calculated functions: Z f!, Z, and Q were close to 
the experimentally observed values, and representative distributions of equilibria were 
obtained. The table below (Table 6.1) shows the dominant species of each system as they 
occurred at the physiological pH 7.4. All the complexes that form at pH 7.4 are highly 
charged (negative; as high as 6-) for all of the systems under investigation. For the 
radiopharmaceuticals considered, PEI-MP predominantly formed hydrolysed complexes, 
whereas with APDDMP, 51 % of the species that formed at pH 7.4 were hydroxides with 
the exception of two complexes: [Snll-APDDMP)'" (48%) and [SnIl2-APDDMPf (1 %). 
In the formation of complexes between APDDMP with Call, Mgll and Zn ll the 
distribution at physiological pH was somewhat mixed for the three systems, with 
hydroxide species being very prominent. 
The blood plasma modelling program ECCLES was used as a means of evaluating the in 
vivo performance of APDDMP and, in essence, explain the bio-distribution of Sn ll -
APDDMP as observed in a study conducted on rats [1]. The animal studies revealed a 
considerably high kidney and bladder uptake, and excretion. Three hypotheses were 
tested by studying trends in the percentage complexation of the Snl! metal-ion and ligand 
concentrations as calculated by ECCLES. The exact values were not as significant to this 
study, but rather the overall trends in ratios and relative concentrations of the metal-ion 
and ligand were utilized to draw the necessary conclusions. The metal-to-ligand ratios of 
the complexed Snl! and APDDMP were compared, as the ratios within the administered 
drug were gradually altered. The hypotheses were established to ascertain whether 
dissociation of the SnlJ-APDDMP complex(es), due to susceptibility of either the Sn ll ion 
or the ligand, was responsible for the observed renal uptake, or even due to rapid 
clearance of the complex as a whole. The calculations proved that the complex is not able 
to withstand the competition within blood plasma and dissociates before it reaches the 
target. This is due to the rapid clearance of the radioactive tin-117m (117mSnll), as 
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observed by Srivastava et al [2] and Zeevaart et al [I]. APDDMP has a stronger affinity 
for physiological metal-ions such as Call, which resulted in the dissociation of the 
radiopharmaceutical, whereupon the 117mSnIl was flushed out via the kidneys, bound to 
histidinate and cysteinate ligands in blood plasma. The change in the levels of APDDMP 
within blood plasma was minimal, or slower, upon dissociation of the drug, whilst the 
total Snl! concentration decreased. 
Therefore, based on the conclusions derived from the ECCLES calculations, which 
substantiated the animal studies, 117mSnII_APDDMP would not be a very effective 
radiopharmaceutical for the treatment of metastatic bone cancer. However, 117mSn 
remains a favourable radionuclide for consideration as a component for bone-seeking 
radiopharmaceuticals. 117mSn_PEI_MP (Snl! and/or SnIV) radiopharmaceuticals could hold 
more promising results. Initial studies have been pursued to establish the formation 
constants [3, 4, 5,] of PEI-MP as prospective drugs. Future efforts should be focused 
toward characterizing 117mSniV -PEI-MP behaviour within blood plasma, and val idation by 
animal trials. Chapter 4 reports the formation constants for Snlv-PEI-MP determined in 
this study. The ligand forms relatively stable complexes with SnIY, which could possibly 
survive the conditions of blood plasma. The complexes that form at pH 7.4 are less 
diverse than with APDDMP. Hence it would be more specific in its action, with 
hopefully less side-effects. The dominant species [SnIV zL(OH)5f, accounts for 
approximately 60% of the SnIV. 
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Table 6.1: The dominant species of each !J}'stem at pH7...f, and their mole fraction 
percentage (1 = 150mM NaCl and T 25°C). 
System Dominant Species Mole Fraction Chapter 
at Percentage at 
pH 7.4 pH 7.4 
[Sn -APDDMP] 48% 2 
[Sn llz-APDDMP(OH)]4- 32% 
[SnllrAPDDMP(OHh]5- 16% 
[Sn Il-APDDMP(OH)]6. 3% 
[SnlIz-APDDMP]3- 1% 
Call-APDDMP I [Ca11zLt 69% 3 
i [CaII2L(OH)t 27.5% 
I [Ca I12LHt 3.5% 
52.0% 3 
][ 3 [Mg 2L] . 39.0% 
. [MgllzLHt 7.5% 
[Mg I12L(OH)2]5. 1.5% 
Znll-APDDMP [Zn il2L(OH)t 54.0% 3 
[Zn1I2L(OHht 40.0% 
[Zn IiL(OH)]6- 5.0% 
~ [Zn llzL]3. 1.0% 
Sn lV -PEI-MP . [Sn1v2L(OH)st 60.0% I 4 
[Sn IV 2L(OH)4] ,. 37% 
3% 
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6.2 Future Work 
The distribution of the APDDMP ligand, solely, in blood plasma remains to be verified 
by animal studies, since only the radionuclide (117mSn) could be detected. It is possible 
that APDDMP on its own could have localized on bone tissue, and more specifically 
accumulated at the tumour site. Zeevaart et al [6] successfully demonstrated that 
APDDMP in fact, a good bone seeker, having achieved a bone uptake of 82.2% in 
animal experiments conducted with 99mTc_APDDMP. Alternatively, this can be 
determined by synthesizing APDDMP with a radioactive-phosphorous label C2P) so as to 
trace the bio-distribution of the ligand - injecting SnH-APDDMP containing a stable 
isotope of tin(II), and thereby purely monitor the localisation of the ligand. 
With APDDMP the formation of neutral species at pH 7.4 were successfully avoided, as 
compared to APD, [MLH]o [8,9]. However, the increased charge introduced by the 
additional methylenephosphonate groups (two) did little to enhance the delivery of the 
radionuclide (117mSnll) to bone, let alone the tumour site. Although liver uptake was 
effectively minimized, the complexes that do form at pH 7.4 are too highly charged 
predominantly [ML ]5- for favourable bone uptake (Table 6.1). The affinity that 
APDDMP exhibits for Call hinders the efficacy of the prospective radiopharmaceutical 
(117mSnll_APDDMP). 
An alternative approach to APDDMP could be to functionalize APD with groups that can 
enhance the stabi! ity of the complex without necessarily affecting the charge of the 
species. By increasing the complex stability, all complexes form more readily at lower 
pH, essentially shifting the complex formation down the pH scale. In so doing, the neutral 
species, [MLH]o, that would typically predominate at pH 7.4 - as with APD would 
make way for the [MLr complex, which becomes present to a larger extent. This can 
possibly be achieved by adding two N,N-dimethylethanamide (or N,N-
dimethylacetamide) groups at the amine of APD, hence a new potential ligand called 
APDDAM (Figure 6.1). 
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APDDAM 
Figure 6.1: Molecular structure of the ligand A PDDAM: 
N,N-di(lv',N'-dimethylethanamide)-l-hydroxy--I-aminopropylidene-
diphosphonate. 
CHAPTER 6 
ECCLES calculations of SnlV -PEI-MP could not be pursued, as the blood plasma model 
for Sn lV has not yet been established. The formation constants should be determined for 
the binding interactions of SnlV with the variety of ligands typically found in blood 
plasma and included in the ECCLES database before any preliminary predictions can be 
made pertaining to the in vivo performance of prospective Sn lV -PEI-MP 
radiopharmaceuticals. However, extensive research has already been conducted on the 
PEI-MP with various metal-ions, including Sn ll [4]. The inclusion of these formation 
constants for PEI-MP into the ECCLES database will giver some insight into the 
interaction of the ligand itself within blood plasma. Figure 6.2 shows the blood plasma 
speciation of PEI-MP, incorporating data obtained from Zeevaart el al [4] into ECCLES. 
Once again a high affinity of the ligand for Call is observed. Interesting to note is that the 
ligand also exists as uncomplexed protonated species H2PEIMP, HPEIMP and H3PEIMP, 
although to a small degree. This could mean that calcium will not displace the tin-ion 
from the PEI-MP complexes as easily as it did with APDDMP. Because, it would be 
expected that any free ligand occurring in the blood plasma would be easily occupied by 
Call-ions, as was the case of APDDMP. Being a polymer, PEI-MP invokes sterk 
hindrance for access of larger metal-ions as opposed to protons (H+ -ions) upon 
dissociation of the Sn-PEI-MP complex. The blood plasma speciation of Sn lV will give 
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further insight as to the susceptibility of the Sn lV -PErMP radiopharmaceutical, 
whereupon predictions can be made as to whether the complex dissociates within blood 
plasma and why, or why not. 
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Figure 6.2: Speciation of PEJ-MP in normal blood plasma, [SnflJ 
8.S xl 0-6 mol.dm-3 and [PEJ-MPJ = 8.S xl 0-5 mol.dm-3 . 
A further aspect for inclusion in the ECCLES blood plasma modelling could be the 
consideration of mixed-metal species. These are similar to the binuclear complexes 
observed within the speciation models reported above, such as Sn"2-APDDMP and Sn1v2_ 
PEI-MP(OH)3, but instead contain two different metal-ions - for example Sn"Ca"-
APDDMP. The likelihood exists that these type of species could form , however their 
formation constants have yet to be determined experimentally. Future studies could 
include the measurement the equilibrium constants for the mixed systems of the major 
physiological metal-ions, namely Call, Mgll and Zn", with SnIl and Sn lV for both ligands 
APDDMP and PEI-MP 
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Experiments pertaining to Snlv-PEI_MP were mainly complicated by the inevitable 
hydrolysis of SnlV in solution resulting in the formation of precipitate, which hampered 
the potentiometric analyses. As considered in Chapter 4. the dual-burette method has to 
be modified and refined, in which the SnlV (in acid medium to retard hydrolysis) is 
titrated against the ligand in solution whilst maintaining fixed pH with a second burette 
containing alkaline solution, typically O.05M NaOH. However, with the current 
technique, a reasonable model was obtained. PEI-MP could still be the subject of future 
research, since - based on the results obtained here it would effectively have a reduced 
liver uptake as opposed to Snll-APDDMP, given that the dominant species is moderately 
charged, [Snlv2L(OH)sf-. PEI-MP has good bone-seeking capabilities, as illustrated in 
pharmacokinetic and biodistribution studies of 99mTc_PEI_MP [7]. Therefore, reasonable 
deposition and accumulation of 117mSniV -PEI-MP in bone can be expected. As with 
APDD\1P, predictions can be made of the behaviour of the Snlv-PEI-MP 
radiopharmaceutical in blood plasma using ECCLES as soon as the Sn lV model is in 
place. Animal studies will give some practical insight as to the biodistribution of 
117mSn1V -PEI-MP. Blood plasma modelling of Snll-PEI-MP was performed by Zeevaart et 
al [4], and revealed promising results, with 82.8% of the Sn ll remaining bound to PEI-
MP. 
Like PEI-MP, which is essentially the polymer of EDTMP, other ligands that exhibit an 
affinity for calcium, and hence hydroxyapatite, can be polymerized. For example, a 
derivative of HEDP. In so doing, continue to exploit the enhanced permeability and 
retention effect, whereby the polymer can be expected to accumulate selectively 111 
regions of increase bone turnover for effective delivery of the radionuclide. 
As the general understanding grows, through persistent probing and refining of 
techniques, more accurate predictions can be made effectively making it possible to 
design radiopharmaceuticals that are more efficient, with minimal side-effects. Better 
ligands can be synthesized, or the existing ones modified to enhance the delivery of 
radionuclides to tumours for pain palliation and the eventual eradication of the cancer. 
Making advances toward the ultimate cure. The search continues. 
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